

NAME: Adrian Michael Di Bisceglie

OFFICE: Department of Internal Medicine
Saint Louis University School of Medicine
1402 South Grand Boulevard
St. Louis, Missouri 63104
Tel: (314) 577-8760
Fax: (314) 268-5108
E-mail: dibiscam@slu.edu

Gastroenterology & Hepatology Research Unit
Saint Louis University School of Medicine
3545 Lafayette Avenue
St. Louis, MO 63104
Phone: (314) 977-9400
Fax: (314) 977-1150

EDUCATION:

1977 Bachelor of Medicine and Bachelor of Surgery (MB BCh), University of the Witwatersrand, Johannesburg, South Africa
1986 Master of Medicine in Internal Medicine (M. Med), University of the Witwatersrand

POSTGRADUATE TRAINING:

1978 Intern: Coronation Hospital, Johannesburg
1980 (Jan-Jun) Senior House Officer: ENT surgery, Johannesburg Hospital
1980-1981 Military Service
1981-1984 Registrar: Dept of Medicine, Baragwanath Hospital, Johannesburg

PRESENT POSITION:

2010 to date Badeeh A. & Catherine V. Bander Chair in Medicine
2009 to date Chairman, Department of Internal Medicine
2006 to date Chief of the Medical Service, Saint Louis University Hospital
1999 to date Chief of Hepatology, Division of Gastroenterology and Hepatology
2000 to date Co-Director, Saint Louis University Liver Center

PREVIOUS POSITIONS HELD:

1984-1985 Physician: Dept of Medicine, Baragwanath Hospital, Johannesburg
1985-1986 Guest Researcher: Liver Diseases Section, NIH, Bethesda, MD
1986-1988 Visiting Associate: LDS, NIDDK, NIH
1989-1991 Senior Investigator: LDS, NIDDK, NIH
1991-1994 Chief, Hepatitis Studies Section, NIDDK, NIH
1992-1994 Chief, Liver Diseases Section, NIDDK, NIH
1994-1999 Associate Chairman, Dept. of Internal Medicine, Saint Louis Univ. School of Medicine
1997-2004 Medical Director, American Liver Foundation
2002-2005 Medical Director of Liver Transplantation, Saint Louis University Hospital
2006-2009 Acting Chairman, Department of Internal Medicine

POSTGRADUATE DIPLOMAS etc:

1978 ECFMG
1982 Fellowship of South African College of Medicine [FCP (SA)]
1984 Registered with South African Medical and Dental Council as Specialist Physician.
1983 Visa Qualifying Examination (VQE)
1986 Master of Medicine in Internal Medicine (M. Med.) for dissertation "Detection of alpha-foetoprotein messenger RNA in human hepatocellular carcinoma tissue".
1988 Federation Licensing Examination (FLEX)
1990 Fellow of the American College of Physicians
1990 Board Certified in Internal Medicine (re-certified in 2002 and 2012)
1991 Board Certified in Gastroenterology (re-certified in 2002)
2010 Board Certified in Transplant Hepatology
2011 Program for Chiefs of Clinical Services, Harvard School of Public Health

ACADEMIC APPOINTMENTS HELD:

1992-1994 Adjunct Associate Professor of Medicine at George Washington University
1994 Professor of Internal Medicine, Saint Louis University (Tenured 1996)

MEDICAL LICENCES HELD:

1988 Maryland (inactive)
1995 Missouri MD

HONORS/AWARDS:

1974-1977 Barlow Rand Medical School Scholarship
1984 James Gear Traveling Fellowship in Virology

- 1984 South African Gastroenterology Society Traveling Fellowship
1984 C.J. Adams Memorial Trust Traveling Fellowship
1993 Invited speaker 6th Annual Hyman J. Zimmerman lecture
1996 Honorary Member of the Argentinean Society of Hepatology
1997 Osler Award for best teacher given by Internal Medicine Residents
1999 Honorary Life Member of the South African Gastroenterology Society (SAGES)
2000 Stephen L. Winter, M.D. 16th Annual Memorial Hepatology Lectureship
Featured Speaker, Univ. of Illinois-Chicago, June 15, 2000
2001 Named Award. American College of Physicians' Adrian M. Di Bisceglie Book
Award given to a graduating medical student at Saint Louis University based upon
performance in General Internal Medicine activities and on outstanding ethical
and humanitarian qualities
2002 Robert L. Peters M.D. lecture on "Management of hepatocellular carcinoma,"
University of Southern California.
2002 Fiterman Foundation Clinical Research in Hepatology or Nutrition (Hugh R. Butt)
Award
2003 Leon Schiff Clinical State of the Art lecture at 2003 Annual Meeting of the
American Association for the Study of Liver Diseases on "Hepatocellular
Carcinoma: Challenges and Opportunities"
2005 11th Annual Leon Schiff lecture at University of Miami on "An Update of
Hepatocellular Carcinoma"
2005 Fifth Biennial Robert Hart Waldman, M.D. Lectureship of Medicine at the
University of Nebraska at Omaha on "The Consequences of Chronic Viral
Hepatitis: Cirrhosis and Hepatocellular Carcinoma".
2005 Leon Schiff lecture at University of Cincinnati, October 2005 on "Hepatocellular
Carcinoma"
2005 Naomi Judd Award by The Friends of the Saint Louis University Liver Center
2009 First Harold Schedl Lecture at University of Iowa, August 20 2009 on "The
Natural History of Hepatitis B and Hepatitis C"
2009 US FDA Advisory Committee Service Award for service on the Blood products
Advisory Committee
2010 Saint Louis University Distinguished Service Award 15 Year Service
2010 Installed as Badeeh A. & Catherine V. Bander Chair in Medicine

RESEARCH INTERESTS:

Viral hepatitis, particularly aspects of its treatment and natural history.
Hepatocellular carcinoma, particularly its relationship to chronic viral hepatitis.

MEMBERSHIP OF PROFESSIONAL SOCIETIES:

American Association for the Study of Liver Diseases (AASLD)
International Society for Interferon Research (ISIR) 1985-1988
American Gastroenterological Association (AGA)
American College of Physicians (Fellow)

European Association for the Study of the Liver (EASL)
International Association for the Study of the Liver (IASL)
International Liver Cancer Association (ILCA)

MISCELLANEOUS:

Organizer and moderator of NIH Combined Clinical Staff Conference on Hepatocellular Carcinoma, December 3rd 1986, NIH.

Organizer (with Drs. E Tabor and RH Purcell) of a national conference on Hepatocellular Carcinoma in North America in Bethesda, September 26-27th 1990.

Organizer (with Dr. Michael A. Gerber) of the AASLD Clinical Research Single Topic Conference on Hepatocellular Carcinoma, St. Louis, MO, March 27-29th 1998

Organizer (with Dr Charles Rice) of the first AASLD Hepatitis Single Topic Conference on “New Therapeutic Strategies for Hepatitis C” in Chicago, June 15 and 16, 2001.

Organizer (with Drs. Gregory Gores and Josep Llovet) of the first AASLD Endpoints Single Topic Conference on “Hepatocellular Carcinoma” in Atlanta, December 2006.

Course Co-Director (with Drs Jake Liang and Norah Terrault) of the 2010 AASLD Postgraduate Course in Boston on Viral Hepatitis.

COMMITTEES:

International

EASL Expert Panel on Hepatocellular Carcinoma 2000

Organizing and Scientific Committee 10th International Symposium on Viral Hepatitis and Liver Disease, Atlanta 2000

Ad-Hoc Grant reviewer for:

- Canadian Institutes of Health Research
- Canadian Liver Foundation
- Italian Ministry of Health
- National Blood Service (UK)
- Raine Medical Research Foundation (University of Western Australia)
- French National Cancer Institute
- Fonds National de la Recherche Luxembourg

Scientific Planning Committee 13th International Symposium on Viral Hepatitis and Liver Disease, Washington DC 2009.

Clinical Practice Guidelines Panel on Hepatocellular Carcinoma for EASL and EORTC (European Organization for Research and Treatment of Cancer) 2010

National

AASLD Research Committee 1991-1994

AASLD Abstract Review Committee (Hepatitis) 1992

AASLD Abstract Selection Committee (Hepatitis C: natural history - Chair) 1995 to 2002
AASLD-IASL Finance Committee 1996-1998
AASLD Strategic Alliance Task Force 1997 – 1999
AASLD Clinical Research Committee 1996 to 2001 (Chair 1999 to 2001)
AASLD Nominating Committee 2001 (elected by AASLD membership)
AASLD Abstract Selection Committee (Hepatitis C: Treatment) 2003–2006 (Chair 2004-2006)
AASLD Public Policy Committee 2003 to date (Chair 2005 - 2007)
AASLD NIH Liaison Committee 2005 to 2007
AASLD Abstract Review Committee (Clinical Hepatobiliary Neoplasia and Liver Imaging) 2008-
AASLD Governing Board 2010-2015

Food and Drug Administration (FDA)

Ad-hoc member FDA Advisory Board on Artificial Liver Support Devices in July 1995
Ad-hoc member FDA Advisory Board on Biological Response Modifiers, July 1995
Consultant, FDA Blood Product Advisory Committee, November 2005
Member, FDA Blood Product Advisory Committee, 2006 to 2009

National Institutes of Health (NIH)

Ad-Hoc member of study sections

- GMA-3 (2003)
- HPBB (2004)
- ZRG1 DIG-B 02 M- (chair 9/05)
- ZCA1 RPRB-O (J1) Cellular and Molecular Biology Special Emphasis panel (9/06)
- ZDK1 GRB-W (J3) Digestive and Liver Diseases Mentoring Program (11/06)
- ZRG1 EMNR-S (55) R. RFA Panel: Indo-US Program on Reproductive Health (7/11)

Other NIH Committees

- Chair, Steering Committee for the HALT-C Trial, 1999 to date
- Planning Committee for 2002 NIH Consensus Conference on Management of Hepatitis C
- Hepatitis Advisory Committee (HAC) of the Adult AIDS Clinical Trial group (AACTG) (now the Hep RAC) 2003 to 2006
- Virology Subcommittee of the AACTG 2004 to 2006
- Planning Committee for 2004 NIH conference on Hepatocellular Carcinoma
- Ad hoc member of the Board of Scientific Advisors of the Clinical Center of the National Institutes of Health, site visit 2004
- Chairman, Hepatocellular Carcinoma group, NIDDK Liver Diseases Action Plan
- Consultant to National Toxicology Program, DHHS, 11th Report on Carcinogens published in February 2005. This report listed the hepatitis B virus and hepatitis C virus as known carcinogens for the first time
- Member, Data Safety Monitoring Board for NIDDK A2ALL Study. 2006 to date
- Member of the Translational Research Working Group of the National Cancer Institute 2005 to 2007 (see report at <http://www.cancer.gov/aboutnci/trwg/finalreport.pdf>)

Miscellaneous

Expert Advisory Panel on Gastroenterology, United States Pharmacopoeial Convention 1995-2000 USP Revision Cycle. 1996 to 2000.

St. Louis Chapter of American Liver Foundation 1997 to 2000

Centers for Disease Control and Prevention to Update Recommendations for the Prevention and Control of HCV Infection (Consultant), July 1998

Hepatitis Council, American Liver Foundation 1997 to date (Chair 1997 to 2004)

Ad-hoc Grant Reviewer for:

- Department of Veterans Affairs, Merit Review Board
- Louisiana Board of Regents
- NIDDK
- NIAID
- NIAAA
- AACTG

EthicAd Steering Committee 1999 to 2000

Member, US Hepatitis Panel for the US Japan Cooperative Medical Sciences Program (USJCMSP), 2005 to date

Institutional Committees

National Institutes of Health (intramural program)

NIDDK Institutional Clinical Review Subcommittee (IRB) 1990-1994

Saint Louis University Medical Center

Graduate Medical Education Committee 1994 to 1999

Education Policy Committee 1994 to 1996

Documentation Practices Committee 1995 to 1998

Curriculum Management Committee 1996 to 1998

Curriculum Oversight Committee 1996 to 1999

Curriculum Design Committee Phase I/II (Co-Chair) 1995 to 1998

Continuing Medical Education Advisory Committee 1995

Cost Reduction Committee 1997 to 1998

SLUCare Facilities and Support Services Committee 1997 to 1998

Governing Board, Saint Louis University Hospital 1998 to 2000

Institutional Review Board 2001-2003

General Clinical Research Center Advisory Committee (GAC) 2001-2002

Member, Saint Louis University Cancer Center

Search Committee for Chairman of the Department of Pathology 2003-5

Review Committee for Department of Comparative Medicine (Chair) 2003/4

Search Committee for Associate Dean for Research 2004

Saint Louis University Conflict of Interest in Research Committee 2005-2006

School of Medicine Dean's Planning Advisory Committee 2006 to 2008

School of Medicine Executive Committee of the Faculty 2006 to date

University Medical Group (UMG) Executive Committee 2006 to date

University Medical Group (UMG) Governing Board 2006 to date

Saint Louis University Hospital Medical Executive Committee 2006 to date

Departmental

Executive Committee 1994 to 1999

Research Committee 1995 to date

Housestaff Evaluation Committee 1994 to 1999

Residency Education Committee 1995 to 1999

Search Committee for Director of Division of Hematology and Oncology (Chair) 1997 to 1998

Internal Medicine Quality Assurance Committee (Chair) 1997 to 1999

SoLUtions task force 2001 to 2002

Executive Committee 2006 to date

TEACHING ACCOMPLISHMENTS:

Internal Medicine Residency Program Director 1994 to 1999

Co-Director Introduction to Clinical Medicine course for sophomore medical students 1996 to 1998

Co-Director of newly introduced Master Clinician course for senior medical students 1996

Co-Director Board Review Course for medicine residents 1995-1997

Director Gastrointestinal Module Course for Sophomore Medical Students 1998 to 1999

Director of newly introduced PORSS course (Patient-Oriented Research Seminar Series) 2003-2004

RESEARCH GRANTS:

Active:

Principal Investigator “1 U01 DK082871-01. “Midwest Hepatitis B Consortium”, sponsored by NIH-NIDDK, \$ 2,537,744, 2008-2015.

Co-investigator R01 DK074515. “Role of HCV sequence variation in pathology”. Sponsored by NIH/NIDDK. 07/15/07 – 06/30/11. John E. Tavis, P.I.

Co-investigator 1R01 DK080711-01. “Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy”. 03/01/08-02/28/13. Sponsored by NIH/NIDDK. Xiaofeng Fan, P.I.

Co-investigator 1RO1DK081817-01A2. “Innate immunity and hepatitis C virus infection”. 8/1/09-6/30/14. Sponsored by NIH/NIDDK \$354,000. Ratna Ray, P.I.

Principal investigator President’s Research Fund “Virus discovery by pyrosequencing”. Sponsored by Saint Louis University. \$25,999. 2010-2011.

Completed:

Principal Investigator “1R21AI076834-01, Cell Culture System for Hepatitis C Virus Genotype 1a” sponsored by NIH-NIAID, \$183,750, 2008-2010.

Co-investigator N01-DK-9-2328 “Utility of the SCCA-IgM Biomarker for HCV-Related HCC” 2/11/10-10/31/10. Sponsored by NCI/NIDDK, subcontract from NERI. \$50,000 Kristin Snow, P.I.

Principal Investigator “NO1-DK092324, Hepatitis C Clinical Trial Clinical Centers: Prevention of Cirrhosis, Hepatic Decompensation and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C” sponsored by NIH-NIDDK-98-4, \$3,225,832, 1999-2010.

Co-Investigator 2U01 CA084951-06 “Early Detection Research Network – effect of medical treatment upon biomarker level study”. Sponsored by NCI. 2004-2009. Timothy Block, P.I. \$52,332 to Dr Di Bisceglie.

Co-Investigator 5U01DK061718-03 “Hyperinsulinemia and pathogenesis of NASH (NASH-CRN)” Sponsored by NIDDK. 2004-2009. Brent A. Neuschwander-Tetri, P.I. Total direct costs \$2,070,964

Co-investigator R21 CA125321. “Variation in NTP use by the HCV polymerase and response to therapy”. 06/07/07 – 05/31/09. NIH/NCI. John E. Tavis, P.I.

Co-Investigator “U01 DK60345-01 Response of HCV to therapy in African Americans” sponsored by NIDDK. 2001-2006, \$1,560,868. John Tavis, P.I.

Principal Investigator “NO1-DK-9-2324 HALT-C Immunology Ancillary Study, sponsored by NIDDK. 1999-2008, \$404,133

Principal Investigator “R01DK5643501 Hepatitis C Viral Quasispecies within the Liver” sponsored by NIH-NIDDK, \$1,649,514. 1999-2004.

Co-investigator “2-R01-DK46602-06, Treatment Study to Compare the Effects of Methotrexate plus UDCA vs. UDCA plus Placebo on the Course of Patients with Primary Biliary Cirrhosis (PBC)” sponsored by University of Texas-Southwestern, \$168,000, 1999-2004. Burton Combes, P.I.

Co-Investigator “2 R44 AI 46064-01 Phase II – Hepatitis C virus quantitation using the 3’ NTR” sponsored by NIAID. 2001-2003. Total direct costs \$677,994. Paul Olivo, P.I.

Principal Investigator “BIO6-002-004 Chemoprevention of hepatocellular carcinoma”. US-Egypt Joint Science and Technology Board. 2002-2004. \$45,500

Co-Investigator “1 U19 AI/DK 48220-01 ZA11 Functional analysis of HCV-B lymphocyte interactions” sponsored by NIDDK and NIAID. 2000-2004. Thomas Chambers, P.I.

Principal Investigator “SLU-2000. Saint Louis University Center of Excellence Award, \$498,480, 2001-2004.

Co-Investigator “3U01 AI25903-18S1. Washington University AIDS Clinical Trial Group”. Sponsored by NIAID. 2005-2006. \$30,547. David Clifford, P.I

Co-Investigator N01-AI-25464. "A Phase I Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Chiron Corporation's HCV E1E2/Mf59 Vaccine Administered to Healthy HCV-Negative Adults". 2003-2004. Robert Belshe, P.I. \$87,670 for laboratory services to Dr Di Bisceglie.

Principal Investigator U01 AI-38858 "Pilot study on effect of antiretroviral therapy (ART) on hepatitis B viral (HBV) infection." 2005-2007. Sponsored by NIH, NIAID and PEPFAR. \$100,000.

EDITORSHIPS:

Co-editor (with Drs. E. Tabor and R.H. Purcell) of "Hepatocellular Carcinoma in North America", Portfolio Publishing.

Editorial Board "HEPATOLOGY" 1990-1991; 1995 to 2005

Associate Editor, "HEPATOLOGY" 1991-1995

Editor, "VIRAL HEPATITIS REVIEWS" 1995 to 2001

Guest Editor, "SEMINARS IN LIVER DISEASE", Vol. 19, Supplement 1, 1999

Editorial Board "TIMELY TOPICS IN MEDICINE - HEPATOLOGY" 1999 to date

Editorial Board "ARCHIVES OF GASTROENTEROLOGY," formerly "HELLENIC JOURNAL OF GASTROENTEROLOGY" 1999 to date

Medical Editor "PROGRESS - American Liver Foundation Newsletter" 1999 to 2004

Co-Editor (with Dr. Bruce Bacon) of "Liver Disease: Diagnosis and Management." Churchill Livingstone, New York, 1999.

Editorial Board for "MINERVA MEDICA," October 2000 to present.

Guest Editor, "CLINICS IN LIVER DISEASE – LIVER TUMORS", Volume 5, Number 1. February 2001.

Editorial board "UPDATE IN HEPATOLOGY". 2001 to 2002.

Editorial board "LIVER TRANSPLANTATION" from 2005 to 2009.

Guest Editor (with Anna Linda Zignego) of "Update in Hepatology: HCV viral infection". 2002; UTET; Torino, Italy.

Editorial board "GUT". 1998-2004.

Co-Editor (with Bruce Bacon, John O'Grady and John Lake) of "Comprehensive Clinical Hepatology" (second edition). Mosby Elsevier, Philadelphia, 2006.

Editorial board "Gastroenterology & Hepatology". 2007 –

Section Editor, Hepatitis C. UpToDate. 2006 to present. www.uptodate.com

International Editorial Board. Hepatology Research 2009 –

Editorial Board "Journal of Interferon and Cytokine Research" 2009 - 2012

PATENTS

Ancestral hepatitis C virus envelope protein sequence. Fan X, Di Bisceglie AM. Provisional patent USTL:004USP1. June 8, 2006.

Compositions and Methods for Amplification and Cloning Of Near Full-Length Viral Genome from Clinical Samples. Fan X, Di Bisceglie AM. Provisional patent number 60/804,194. June 8, 2006. Final patent US 7,786,294 B2 issued August 31st 2010.

Identification of multivalent viral envelope protein epitopes. Fan X, Di Bisceglie AM. Provisional Patent USTL:005USP1. December 28, 2006.

ORIGINAL PUBLICATIONS:

1. Phaeochromocytoma. Huddle KRL, **Di Bisceglie AM** and Feldman C. S Afr Med J 1982;61:286-288.
2. Myocardial infarction in an intensive care unit for blacks. **Di Bisceglie AM**, Miller MT, Blumsohn D. S Afr Med J 1982;61:902-904.
3. Multiple myeloma and pernicious anaemia. **Di Bisceglie AM**, Hodgkinson HJ. S Afr Med J 1982;62:535-536.
4. Continuous peritoneal dialysis in a developing population: Problems seen at Baragwanath Hospital. **Di Bisceglie AM**, DVA Mzamane. S Afr Med J 1983; 63:405-406.
5. Perforated duodenal ulcer associated with endoscopy resulting in pancreatic abscess. **Di Bisceglie AM**, Segal I, Ming RHC, Pantanowitz D, Elisseos C. S Afr Med J 1983; 63:461-462.
6. Primary sclerosing cholangitis. **Di Bisceglie AM**, Segal I, Hodgkinson H, Posen J. Cent Afr J Med 1983;29:125-128.

7. Bacterial peritonitis due to an infected dialysis catheter. **Di Bisceglie AM**, Mzamane DVA. *S Afr Med J* 1983; 64:718-719.
8. Pitfalls in the diagnosis of gestational choriocarcinoma. Krige LP, **Di Bisceglie AM**. *S Afr Med J* 1984;65:26-27.
9. Pancreatic endocrine tumor presenting with obstructive jaundice. **Di Bisceglie AM**, Segal I, Mannell A, Posen J. *Am J Gastroenterol* 1984;79:43-45.
10. Benign extrinsic oesophageal dysphagia. **Di Bisceglie AM**, Segal I, Mirwis J. *S Afr Med J* 1985;67:219-221.
11. Transudative ascites with a high protein content. **Di Bisceglie AM**, Schamroth CL. *S Afr Med J* 1985;67:941-942.
12. Clinical and serological events accompanying changes in hepatitis B viral replication: case reports. Dusheiko GM, Bowyer S, Paterson AC, Song E, **Di Bisceglie AM**, Kew MC. *Liver* 1985;5:77-83.
13. Detection of markers of hepatitis B virus infection in urine of chronic carriers. **Di Bisceglie AM**, Dusheiko GM, Kew MC. *J Med Virol* 1985;16:337-341.
14. Smoking as a risk factor in hepatocellular carcinoma. Kew MC, **Di Bisceglie AM**, Paterson AC. *Cancer* 1985;56:2315-2317.
15. Recombinant leukocyte interferon treatment of chronic hepatitis B. Dusheiko GM, **Di Bisceglie AM**, Bowyer S, Sachs E, Ritchie M, Schoub B, Kew MC. *Hepatology* 1985;5:556-560.
16. The liver in biliary obstruction due to chronic pancreatitis. **Di Bisceglie AM**, Paterson AC and Segal I. *Liver* 1985;5:189-195.
17. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: A pilot study. Sachs E, **Di Bisceglie AM**, Dusheiko GM, Song E, Lyons SF, Schoub BD, Kew MC. *Br J Cancer* 1985;52:105-109.
18. Hyponatraemia complicating treatment of myxoedema coma. Berkowitz I, **Di Bisceglie AM**. *S Afr Med J* 1986; 69:136-137.
19. Obstructive jaundice in South African Blacks. **Di Bisceglie AM**, Oettle GJ, Hodkinson HJ, Segal I. *J Clin Gastroenterol* 1986; 8:538-541.
20. Pityriasis Rotunda - a cutaneous manifestation of hepatocellular carcinoma in South African blacks. **Di Bisceglie AM**, Hodkinson HJ, Berkowitz I, Kew MC. *Arch Dermatol* 1986;122:802-804.

21. Recombinant leucocyte interferon treatment of chronic hepatitis B: an analysis of two therapeutic trials. Dusheiko GM, Paterson AC, Pitcher L, Kassianides C, **Di Bisceglie AM**, Song E, Kew MC. *J Hepatology* 1986;3:5199-5207.
22. Prevalence of hepatitis B virus infection among black children in Soweto. **Di Bisceglie AM**, Kew MC, Dusheiko GM, Berger EL, Song E, Paterson AC, Hodgkinson HJ. *Br Med J* 1986;292:1440-1442.
23. Detection of alpha-foetoprotein messenger RNA in human hepatocellular carcinoma and hepatoblastoma tissue. **Di Bisceglie AM**, Dusheiko GM, Paterson AC, Alexander J, Shouval D, Lee C-S, Beasley PR, Kew MC. *Br J Cancer* 1986;54:779-785.
24. Treatment of chronic non A, non B hepatitis with recombinant human alpha interferon: preliminary report. Hoofnagle JH, Mullen KD, Jones DB, Rustgi VK, **Di Bisceglie AM**, Peters M, Waggoner JG, Park Y, Jones EA. *N Eng J Med* 1986; 315:1575-1578.
25. Factors predisposing to central corneal ulceration in a developing population. **Di Bisceglie AM**, Carmichael TR. *S Afr Med J* 1987;71:769-770.
26. A randomized controlled trial of a 4 month course of recombinant human alpha interferon in patients with chronic type B hepatitis. **Di Bisceglie AM**, Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi VK, Avigan MI, Park Y, Waggoner JG, Jones EA. In, Schellekens H, Cantell K. *Proceedings of the 1986 ISIR/TNO Meeting*. 1987 Martinus Nijhoff. Dordrecht.
27. Hepatitis B virus DNA in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen following anti-viral therapy. **Di Bisceglie AM**, Waggoner JG, Hoofnagle JH. *Gastroenterology* 1987;93:1236-1241.
28. Therapy of chronic viral hepatitis: chronic hepatitis D and non A, non B hepatitis. Hoofnagle JH, **Di Bisceglie AM**. In, Zuckerman AJ, ed. *Viral Hepatitis and Liver Disease*. Alan R. Liss, New York 1988;823-830.
29. Effect of recombinant human gamma interferon therapy on immune function in patients with chronic type B hepatitis. Lisker-Melman M, Peters M, Ambrus J, Witzel N, **Di Bisceglie AM**, Kassianides C, Park Y, Murray L, Paxton H, Hoofnagle JH, in: Zuckerman AJ, ed. *Viral Hepatitis and Liver Disease*. Alan R. Liss, New York 1988;868-871.
30. Alpha interferon treatment of patients with decompensated chronic type B hepatitis. Kassianides, **Di Bisceglie AM**, Hoofnagle JH, Mullen KD, Peters M, Rustgi VK, Jones DB, Lisker-Melman M, Park Y, Waggoner J, Jones EA, in: Zuckerman AJ, ed. *Viral Hepatitis and Liver Disease*. Alan R. Liss, New York 1988;840-843.

31. A randomized, controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B. Hoofnagle JH, Peters M, Mullen K, Jones DB, Rustgi VK, **Di Bisceglie AM**, Hallahan C, Park Y, Meschievitz C, Jones EA. *Gastroenterology* 1988;95:1318-1325.
32. The genesis of chronic pancreatitis in the South African black population. Segal I, Lerios M, MacPhail AP, **Di Bisceglie AM**, Grieve TP. *S Afr Med J* 1988;74:385-386.
33. Hepatocellular carcinoma: Molecular biology of its growth and relationship to hepatitis B virus infection. **Di Bisceglie AM**. *Med Clin N Am* 1989;73:985-998.
34. Multiple verruciform xanthoma of the upper aerodigestive tract in a child with a systemic lipid disorder. Travis WD, Davis GE, Tsokos M, Lebovics R, Merrick HFW, Miller SPF, Gregg RE, **Di Bisceglie AM**, Parker RI, Ishak KG, Filling-Katz MR. *Am J Surg Path* 1989;13:309-316.
35. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. **Di Bisceglie AM**, Hoofnagle JH. *Cancer* 1989;64:2117-2120.
36. Pityriasis rotunda: a new cutaneous marker of hepatocellular carcinoma? **Di Bisceglie AM**, Hodkinson HJ, Berkowitz I, Kew MC. *Br J Dermatol* 1989;120:545-549.
37. Primary hepatic lymphoma of the liver in a patient with acquired immunodeficiency syndrome and chronic hepatitis B. Lisker-Melman M, Pittaluga S, Pluda JM, Kleiner DE, Thompson P, Martin P, Yarchoan R, **Di Bisceglie AM**. *Am J Gastroenterol* 1989; 84:1445-1448.
38. Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha interferon. Lisker-Melman M, Webb D, **Di Bisceglie AM**, Kassianides C, Martin P, Rustgi V, Waggoner JG, Park Y, Hoofnagle JH. *Ann Intern Med* 1989;111:479-483.
39. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Martin P, **Di Bisceglie AM**, Kassianides C, Lisker-Melman M, Hoofnagle JH. *Gastroenterology* 1989;97:1559-1561.
40. Intrahepatic markers of hepatitis delta virus infection: a study by in situ hybridization. Negro F, Bonino F, **Di Bisceglie AM**, Hoofnagle JH, Gerin JL. *Hepatology* 1989; 10:916-920.
41. Interleukin-2 induces profound reversible cholestasis: A detailed analysis in treated cancer patients. Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, **Di Bisceglie AM**, Hoofnagle JH, Yolles P, Rosenberg SA, Lotze MT. *J Clin Oncol* 1989;17:1852-1862.
42. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. **Di Bisceglie AM**, Martin P, Kassianides C, Lisker-Melman M,

Murray L, Waggoner JG, Goodman Z, Banks SM, Hoofnagle JH. *N Eng J Med* 1989;321:1506-1510.

43. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. **Di Bisceglie AM**, Rustgi VK, Kassianides C, Lisker-Melman M, Park Y, Waggoner JG, Hoofnagle JH. *Hepatology* 1990;11:266-270.
44. Cholesteryl ester storage disease: Hepatopathology and effects of therapy with lovastatin. **Di Bisceglie AM**, Ishak KG, Rabin L, Hoeg J. *Hepatology* 1990;11:764-772.
45. Significance of hepatitis B core antigen in the liver in patients with chronic hepatitis B and its relation to hepatitis B virus DNA. Yoo JY, Kim HY, Park CK, Khang SK, Jeong JW, Chung WK, **Di Bisceglie AM**, Hoofnagle JH. *J Gastro Hepatol* 1990;5:239-243.
46. A randomized, double blind placebo-controlled trial of recombinant human alpha interferon therapy for chronic non-A, non-B (type C) hepatitis. **Di Bisceglie AM**, Martin P, Kassianides C, Lisker-Melman M, Goodman Z, Banks SM, Hoofnagle JH. *J Hepatol* 1990;11:S36-S42.
47. Therapy of chronic delta hepatitis with interferon alfa-2b. **Di Bisceglie AM**, Martin P, Lisker-Melman M, Kassianides C, Korenman J, Bergasa N, Baker B, Hoofnagle JH. *J Hepatol* 1990;11:S151-S154.
48. Oligoclonal immunoglobulin bands in serum in association with chronic viral hepatitis. Tsianos EV, **Di Bisceglie AM**, Papadopoulos NM, Costello R, Hoofnagle JH. *Am J Gastroenterol* 1990;85:1005-1008.
49. Risk of Non-A, Non-B (type C) hepatitis through sexual or household contact with carriers. Everhart JE, **Di Bisceglie AM**, Murray L, Alter HJ, Melpolder JJ, Kuo G, Hoofnagle JH. *Ann Intern Med* 1990;112:544-545.
50. Detection of hepatitis B virus DNA in serum by polymerase chain reaction: Application for clinical diagnosis. Kaneko S, Miller RH, **Di Bisceglie AM**, Feinstone SM, Hoofnagle JH, Purcell RH. *Gastroenterology* 1990;99:799-804.
51. Hepatitis B virus DNA detection and comparison with hepatitis B surface antigen. Kaneko S, Miller RH, **Di Bisceglie AM**, Feinstone SM, Hoofnagle JH, Purcell RH. *Gastroenterol Japonica* 1990;25:S57-S61.
52. Hepatitis B viral replication within the human spleen. **Di Bisceglie AM**, Hoofnagle JH. *J Clin Microbiol* 1990;28:2850-2852.
53. Antiviral therapy of viral hepatitis. Hoofnagle JH, **Di Bisceglie AM**. In, Galasso Whitley, Merigan, eds. *Antiviral Agents and Viral Diseases of Man*, 3rd Edition. 1990;12:415-459.

54. Treatment of chronic non A, non B (type C) hepatitis. **Di Bisceglie AM**. In, Hollinger B, Lemon SM, Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Williams and Wilkins, Baltimore 1991;623-626.
55. Loss of hepatitis B surface antigen (HBsAg) following treatment of chronic hepatitis B with alpha interferon. Korenman JC, Baker BL, Waggoner JG, **Di Bisceglie AM**, Hoofnagle JH. In, Hollinger B, Lemon SM, Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Williams and Wilkins, Baltimore 1991;639-640.
56. Detection of hepatitis delta virus RNA by in situ hybridization: Virological implications. Negro F, Pacchioni D, **Di Bisceglie AM**, Gerin JL, Bussolati G, Bonino F. In, Schiraldi O, Pastore G, Dentico P, eds. *Progress and prospects in viral hepatitis*. Gerni Editori, San Severo 1991;367-370.
57. Detection of hepatitis C viral RNA by the polymerase chain reaction. Cristiano K, Baker B, **Di Bisceglie AM**, Feinstone SM. In, Hollinger B, Lemon SM, Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Williams and Wilkins, Baltimore 1991;374-375.
58. Blood-borne non-A, non-B hepatitis: Detection and identification of hepatitis C virus and disease-associated antigen (HCV Ag) in hepatocytes. Krawczynski K, Kuo G, **Di Bisceglie AM**, Bradley D, Houghton M, Alter M, Ebert J. In, Hollinger B, Lemon SM, Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Williams and Wilkins, Baltimore 1991;434-435.
59. Determination of hepatitis B virus DNA in serum using the polymerase chain reaction: Clinical significance and correlation with serological and biochemical markers. Baker BL, **Di Bisceglie AM**, Kaneko S, Miller R, Feinstone SM, Waggoner JG, Hoofnagle JH. *Hepatology* 1991;13:632-636.
60. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. **Di Bisceglie AM**, Order SE, Klein J, Waggoner J, Sjogren M, Kuo G, Houghton M, Choo Q-L, Hoofnagle J. *Am J Gastroenterol* 1991;86:335-338.
61. Long term remission in chronic hepatitis B after alpha-interferon therapy. Korenman JC, Baker B, Waggoner JG, Everhart JE, **Di Bisceglie AM**, Hoofnagle JH. *Ann Intern Med* 1991;114:629-634.
62. Recurrence of hepatitis C virus infection following orthotopic liver transplantation. Martin P, Munoz SJ, **Di Bisceglie AM**, Rubin R, Waggoner JG, Armenti VT, Moritz MJ, Jarrell BE, Maddrey WC. *Hepatology* 1991;719-721.
63. Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: Detection by the polymerase chain reaction using multiple primer sets. Cristiano K, **Di Bisceglie AM**, Hoofnagle JH, Feinstone SM. *Hepatology* 1991;14: 51-55.

64. Detection of hepatitis C viral RNA in serum of a patient with acute non A, non B hepatitis. Waxman I, Baker B, Feinstone SM, **Di Bisceglie AM**. *Am J Gastroenterol* 1991;86:1240-1242.
65. Nodular regenerative hyperplasia of the liver associated with the hypereosinophilic syndrome. Baker B, **Di Bisceglie AM**, Horwitz ES, Levitt R, Axiotis C. *J Clin Gastroenterol* 1991;13:452-456.
66. Chronic fatigue syndrome: Lack of association with hepatitis C virus infection. Dale JK, **Di Bisceglie AM**, Hoofnagle JH, Straus SE. *J Med Virol* 1991;13:452-456.
67. Diagnostic problems in clinical hepatology. A 20-year old man with persistent aminotransferase elevations. **Di Bisceglie AM**, Goodman ZD. *Semin Liv Dis* 1991;11:175-181.
68. The significance of antibody to hepatitis C virus in chronic hepatitis B. Fong T-L, **Di Bisceglie AM**, Waggoner JG, Hoofnagle JH. *Hepatology* 1991;14:64-67.
69. Decrease in serum hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C. Shindo M, **Di Bisceglie AM**, Cheung L, Shih J W-K, Cristiano K, Feinstone SM, Hoofnagle JH. *Ann Intern Med* 1991;115:700-706.
70. Radiologic findings in hepatocellular carcinoma: The National Institutes of Health Experience. Feuerstein IM, Chow CK, Miller DL, Carrasquillo JA, Lotze MT, **Di Bisceglie AM**. *Hepatocellular carcinoma in North America*. Portfolio Publishing, Houston 1991;255-272.
71. Replacement therapy for inherited enzyme deficiency: Macrophage-targeted glucocerebrosidase for Gaucher Disease. Barton NW, Brady RO, Dambrosia JM, **Di Bisceglie AM** and 17 others. *N Engl J Med* 1991;324:1464-70.
72. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, **Di Bisceglie AM**. *J Clin Invest* 1991;88:1058-1060.
73. Long term clinical and histopathological follow up of chronic posttransfusion hepatitis. **Di Bisceglie AM**, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. *Hepatology* 1991;14:969-974.
74. Development of cirrhosis after chronic type B hepatitis: A clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Moreno-Otero R, Garcia-Monzon C, Garcia-Sanchez A, Buey LG, Pajares JM, **Di Bisceglie AM**. *Am J Gastroenterol* 1991;86:560-564.

75. The significance of antibody hepatitis C virus in patients with chronic hepatitis B. Fong TLF, **Di Bisceglie AM**, Waggoner JG, Banks SM, Hoofnagle JH. In, Hollinger B, Lemon SM, Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Williams and Wilkins, Baltimore 1991; 447-448.
76. Autoimmune thyroid disease associated with recombinant human alpha interferon therapy in patients with chronic viral hepatitis. Lisker-Melman M, **Di Bisceglie AM**, Usala SJ, Weintraub B, Murray L, Hoofnagle JH. *Gastroenterology* 1992;102:2155-2160.
77. Measurements of iron status in patients with chronic hepatitis. **Di Bisceglie AM**, Axiotis CA, Hoofnagle JH, Bacon BR. *Gastroenterology* 1992;102:2108-2113.
78. Recurrence of hepatitis B and delta hepatitis following orthotopic liver transplantation. Lucey MR, Graham D, Martin P, **Di Bisceglie AM**, Rosenthal S, Waggoner JG, Merion RM, Campbell DA, Nostrant TT, Appelman H. *GUT* 1992;33:1390-1396.
79. Acute exacerbation of liver disease during interferon alpha therapy for chronic hepatitis C. Shindo M, **Di Bisceglie AM**, Hoofnagle JH. *Gastroenterology* 1992;102:1406-1408.
80. Absence of hepatitis C viral RNA in saliva and semen of patients with chronic hepatitis C. Fried MW, Shindo M, Fong TL, Fox PC, Hoofnagle JH, **Di Bisceglie AM**. *Gastroenterology* 1992;102:1306-1308.
81. Transforming growth factor alpha in human hepatocellular carcinoma and co-expression with hepatitis B surface antigen in adjacent liver. Hsia C-C, Axiotis CA, **Di Bisceglie AM**, Tabor E. *Cancer* 1992;70:1049-1056.
82. A pilot study of ribavirin therapy for chronic hepatitis C. **Di Bisceglie AM**, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. *Hepatology* 1992;16:649-654.
83. A pilot study of 2'3'-dideoxyinosine for the treatment of chronic hepatitis B. Fried MW, Korenman JC, **Di Bisceglie AM**, Park Y, Waggoner JG, Mitsuya H, Hartman NR, Yarrowan R, Broder S, Hoofnagle JH. *Hepatology* 1992;16:861-864.
84. Hepatitis C virus antigen in hepatocytes: Immunomorphologic detection and identification. Krawczynski K, Beach MJ, Bradley DW, Kuo G, **Di Bisceglie AM**, Houghton M, Reyes GR, Kim JP, Choo Q-L, Alter MJ. *Gastroenterology* 1992;103: 622-629.
85. Increased expression of transforming growth factor alpha after transfection of a human hepatoblastoma cell line with the hepatitis B virus. Tabor E, Farshid M, **Di Bisceglie AM**, Hsia CC. *J Med Virol* 1992;37:271-273.

86. Massive intrahepatic hemorrhage following routine liver biopsy in a patient with rheumatoid arthritis treated with methotrexate. Cash JM, Swain M, **Di Bisceglie AM**, Wilder RL, Crofford LJ. *J Rheumatol* 1992;19:1466-1468.
87. Mutations of p53 gene in hepatocellular carcinoma: Roles of hepatitis B virus and Aflatoxin contamination in the diet. Hsia CC, Kleiner DE, Axiotis CA, **Di Bisceglie AM**, Nomura AMY, Stemmerman GN, Tabor E. *JNCI* 1992;84:1638-1641.
88. Hepatitis C virus during acute infection in the chimpanzee. Shindo M, **Di Bisceglie AM**, Biswas R, Mihalik K, Feinstone SM. *J Inf Dis* 1992;166:424-427.
89. Long-term follow up of patients with chronic hepatitis C treated with alpha-interferon. Shindo M, **Di Bisceglie AM**, Hoofnagle JH. *Hepatology* 1992;15:1013-1016.
90. Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets. Cristiano K, **Di Bisceglie AM**, Hoofnagle JH, Feinstone SM. *Arch Virol* 1992;[suppl]4:172-178.
91. Antiviral therapy of hepatitis C: Present and Future. Hoofnagle JH, **Di Bisceglie AM**, Shindo M. *J Hepatol* 1993;17:S130-S136.
92. The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease, type C. Patterson MC, **Di Bisceglie AM**, Higgins JJ, Abel RB, Schiffmann R, Parker CC, Argoff CE, Grewal RP, Yu K, Pentchev PG, Brady RO, Barton NW. *Neurology* 1993;43:61-64.
93. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Hoofnagle JH, **Di Bisceglie AM**, Waggoner, JG, Park Y. *Gastroenterology* 1993;104:1116-1121.
94. Gaucher Disease: Abdominal MR Imaging findings in 46 patients. Hill SC, Damaska BM, Ling A, Patterson K, **Di Bisceglie AM**, Brady RO, Barton NW. *Radiology* 1992; 184:561-566.
95. Prolonged alpha interferon therapy for chronic delta hepatitis: Effect on liver histopathology. Kleiner D, **Di Bisceglie AM**, Axiotis CA, Hoofnagle JH. In, Bonino F, Taylor J, Hadziyannis S, eds. *Hepatitis Delta Virus*. Wiley-Liss, New York 1992;365-371.
96. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Fried MW, Draguesku JO, Shindo M, Simpson LH, Banks SM, Hoofnagle JH, **Di Bisceglie AM**. *Dig Dis Sci* 1993;38:631-636.
97. Persistence of Hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Fong T-L, **Di Bisceglie AM**, Gerber MA, Waggoner JG, Hoofnagle JH. *Hepatology* 1993;18:1313-1318.

98. B cell epitopes on the hepatitis C virus nucleocapsid protein determined by human monospecific antibodies. Akatsuka T, Donets M, Scaglione L, Ching W-M, Shih JW-K, **Di Bisceglie AM**, Feinstone SM. *Hepatology* 1993;18:503-510.
99. A 39-year-old man with chronic hepatitis, elevated serum ferritin values, and a family history of hemochromatosis. Bacon BR, Fried MW, **Di Bisceglie AM**. *Seminars in Liver Disease* 1993;13:101-105.
100. A randomized, controlled trial of recombinant alpha interferon therapy for chronic hepatitis B. **Di Bisceglie AM**, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, Bergasa NV, Waggoner JG, Park Y, Hoofnagle JH. *Am J Gastroenterol* 1993;88:1887-1892.
101. Changes in hepatitis C virus antigen in liver with antiviral therapy. **Di Bisceglie AM**, Hoofnagle JH, Krawczynski K. *Gastroenterology* 1993;105:858-862.
102. Detection and quantitation of hepatitis C virus RNA in serum using the polymerase chain reaction and a colorimetric enzymatic detection system. Shindo M, **Di Bisceglie AM**, Silver J, Limjoco T, Hoofnagle JH, Feinstone SM. *J Virol Methods* 1994;48:65-72.
103. Therapy of chronic hepatitis B with a 6 month course of ribavirin. Fried MW, Fong T-L, Swain MG, Park Y, Beames M, Banks SM, Hoofnagle JH, **Di Bisceglie AM**. *J Hepatol* 1994;21:145-150.
104. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. Fong T-L, **Di Bisceglie AM**, Biswas R, Waggoner JG, Wilson L, Clagett J, Hoofnagle JH. *J Med Virol* 1994;43:155-158.
105. The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. Shindo M, **Di Bisceglie AM**, Akatsuka T, Fong T-L, Donets M, Hoofnagle JH, Feinstone SM. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. *Viral Hepatitis and Liver Disease*. Springer-Verlag, New York, 1994;147-149.
106. Hepatitis C viral RNA and hepatic cytokine expression in chronic hepatitis C: The effect of alpha interferon therapy. Shindo M, Hoofnagle JH, **Di Bisceglie AM**. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. *Viral Hepatitis and Liver Disease*. Springer-Verlag, New York, 1994;627-630.
107. Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma. Mangia A, Vallari D, **Di Bisceglie AM**. *J Med Virol* 1994;43:125-128.
108. The development of a mutation in the pre-core region of the hepatitis B virus in a chronically-infected individual. Lee JH, Zeldis JB, Baker B, **Di Bisceglie AM**. *Gastroenterology* 1994;106:243-247.

109. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. **Di Bisceglie AM**, Simpson LH, Lotze MT, Hoofnagle JH. *J Clin Gastroenterol* 1994;19:222-226.
110. Diagnosis of chronic hepatitis C: Comparison of immunoassays and the polymerase chain reaction. Silva E, Hosein B, Boyle R, Fang C, Shindo M, Waggoner J, Hoofnagle J, **Di Bisceglie AM**. *Am J Gastroenterol* 1994;89:493-496.
111. RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. Hsia CC, **Di Bisceglie AM**, Kleiner DE, Farshid M, Tabor E. *J Med Virol* 1994;44:67-73.
112. Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis. Simpson LH, Battegay M, Hoofnagle JH, Waggoner JG, **Di Bisceglie AM**. *Dig Dis Sci* 1994;39:2650-2655.
113. The physical state of the negative strand of HCV RNA in serum. Shindo M, **Di Bisceglie AM**, Akatsuka T, Fong TL, Donets M, Hoofnagle JH, Feinstone SM. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. *Viral Hepatitis and Liver Disease*. Springer-Verlag, New York 1994;147-149.
114. Hepatitis C viral RNA and hepatic cytokine expression in chronic hepatitis C: The effect of alpha interferon therapy. Shindo M, Hoofnagle JH, **Di Bisceglie AM**. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. *Viral Hepatitis and Liver Disease*. Springer-Verlag, New York 1994;627-630.
115. The physical state of the negative strand of hepatitis C virus RNA in serum. Shindo M, **Di Bisceglie AM**, Akatsuka T, Fong T-L, Donets M, Hoofnagle JH, Feinstone SM. *Proc Natl Acad Sci USA* 1994;91:8719-8723.
116. Increasing HCV RNA levels in hemophiliacs: Relationships to human immunodeficiency infection and liver disease. Eyster ME, Fried MW, **Di Bisceglie AM**, Goedert JJ. *Blood* 1994;84:1020-1023.
117. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. **Di Bisceglie AM**, Bacon BR, Kleiner DE, Hoofnagle JH. *J Hepatol* 1994;21:1109-1112.
118. Changes in levels of HCV-RNA and hepatitis C viral antigen associated with interferon-alpha therapy of chronic hepatitis C. **Di Bisceglie AM**, Shindo M, Krawczynski K, Hoofnagle JH. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. *Viral Hepatitis and Liver Disease*. Springer-Verlag, New York 1994;610-613.

119. Genotypic analysis of hepatitis C virus in American patients. Mahaney K, Tedeschi V, Maertens G, **Di Bisceglie AM**, Vergalla J, Hoofnagle JH, Sallie R. *Hepatology* 1994;20:1405-1411.
120. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, **Di Bisceglie AM**. *J Med Virol* 1994;44:389-392.
121. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Olynyk JK, Reddy RK, **Di Bisceglie AM**, Jeffers LJ, Parker TL, Radick JL, Schiff ER, Bacon BR. *Gastroenterology* 1995;108:1104-1109.
122. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus encoded peptides binding to HLA-A2.1 molecules. Battegay M, Fikes J, **Di Bisceglie AM**, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, Berzofsky JA, Hoofnagle JH, Feinstone SM, Akatsuka T. *J Virol* 1995;69:2462-2470.
123. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with alpha interferon. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, **Di Bisceglie AM**. *Gastroenterology* 1995;109:540-546.
124. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virological and histologic features. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, **Di Bisceglie AM**, Hoofnagle J. *Ann Intern Med* 1995;123:330-337.
125. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Eyster ME, Sanders JC, Battegay M, **Di Bisceglie AM**. *Dig Dis Sci* 1995;40:1583-1588.
126. Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B. Morimitsu Y, Kleiner DE, Conjeevaram HS, Hsia CC, **Di Bisceglie AM**, Tabor E. *Hepatology* 1995;22:1021-1026.
127. Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. Mican J, **Di Bisceglie AM**, Fong TL, Travis WD, Kleiner DE, Baker B, Metcalfe DD. *Hepatology* 1995;22:1163-1170.
128. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. Alter HJ, Sanchez-Pescador R, Ureda MS, Wilber JC, Lagier RJ, **Di Bisceglie AM**, Shih JW, Neuwald PD. *J Viral Hepatitis* 1995;2:121-132.

129. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. McKenzie R, Fried MW, Sallie R, Conjeevaram H, **Di Bisceglie AM**, et al. *N Engl J Med* 1995;333:1099-1105.
130. Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. O'Brien TR, Diamondstone L, Fried MW, Aledort LM, Eichinger S, Eyster ME, Hilgartner MW, White G, **Di Bisceglie AM**, Goedert JJ. *Am J Hematol* 1995;49:201-206.
131. Fulminant hepatitis in patients undergoing liver transplantation: Evidence for a non-A, non-B, non-C, non-D, and non-E syndrome. Ferraz ML, Silva AE, Macdonald GA, Tsarev SA, **Di Bisceglie AM**, Lucey MR. *Liver Transpl Surg* 1996;2:60-66.
132. Ribavirin as therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. **Di Bisceglie AM**, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Wright D, Hoofnagle JH. *Ann Intern Med* 1996;123:897-903.
133. Seizures during alpha interferon therapy. Shakil AO, **Di Bisceglie AM**, Hoofnagle JH. *J Hepatol* 1996;24:48-51.
134. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. Conry-Cantilena C, Van Raden M, Gibble J, Melpolder J, Shakil O, Viladomiu L, Chung L, **Di Bisceglie AM**, Hoofnagle J, Shih J, Kaslow R, Ness P, Alter HJ. *N Engl J Med* 1996;334:1691-1696.
135. Prolonged therapy of chronic hepatitis C with ribavirin. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, **Di Bisceglie AM**. *J Vir Hep* 1996;3:247-252.
136. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy of chronic hepatitis B. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, **Di Bisceglie AM**. *Am J Gastroenterol* 1996;91:1-6.
137. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. Mangia A, Chung Y-H, Hoofnagle JH, Birkenmeyer L, Mushahwar I, **Di Bisceglie AM**. *Dig Dis Sci* 1996;41:2447-2452.
138. An aflatoxin-associated, mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Soini Y, Chiq SC, Bennett WP, Groopman JD, Wang J-S, DeBenedetti VMG, Cawley H, Welsh JA, Hansen C, Bergasa N, Jones A, **Di Bisceglie AM**, Trivers GE, Sandoval CA, Calderon IE, Munoz Espinosa LE, Harris CC. *Carcinogenesis* 1996;17:1007-1012.
139. Rapid development of hepatic alpha-1-antitrypsin globules after liver transplantation for chronic hepatitis C. Combs C, Brunt EM, Solomon H, Bacon BR, Brantly M, **Di Bisceglie AM**. *Gastroenterology* 1997;112:1372-1375.

140. Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. Poulos JE, Weber JD, Bellezzo JM, **Di Bisceglie AM**, Britton RS, Bacon BR, Baldassare JJ. *Am J Physiol* 1997;273:G804-G811.
141. Assessment of monoethylglycinexylidide as a measure of liver function for patients with viral hepatitis. Elin RJ, Fried M, Sampson M, Ruddel M, Kleiner DE, **Di Bisceglie AM**. *Clin Chem* 1997;43:1952-1957 .
142. Geographic distribution and genetic variability of hepatitis delta virus genotype 1. Shakil AO, Hadziyannis S, Hoofnagle JH, **Di Bisceglie AM**, Gerin JL, Casey JL. *Virology* 1997;234:160-167.
143. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis. Arns PA, Adedoyin A, **Di Bisceglie AM**, Waggoner JG, Hoofnagle JH, Wilkinson GR, Branch RA. *Clinical Pharmacology and Therapeutics* 1997;62:527-537.
144. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, **Di Bisceglie AM**. *Clin Infect Dis* 1998;26:895-897.
145. Porphyria cutanea tarda, hepatitis C and *HFE* gene mutation in North America. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, **Di Bisceglie AM**, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RN. *Hepatology* 1998;27:1661-1669.
146. Pruritus as a presenting symptom of chronic hepatitis C. Chia S-C, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, **Di Bisceglie AM**. *Dig Dis Sci* 1998;43:2177-2183.
147. Hepatitis C virus infection in the mothers and infants cohort study. Granovsky MO, Minkoff HL, Tess BH, Waters D, Hatzakis A, Devoid D, Landesman SH, Rubenstein A, **Di Bisceglie AM**, Goedert JJ. *Pediatrics* 1998;102:355-359.
148. Spontaneous bacterial peritonitis caused by infection with *Listeria Monocytogenes*: A case report and review of the literature. Jayaraj K, **Di Bisceglie AM**, Gibson S. *Am J Gastroenterol* 1998;93:1556-1558.
149. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S, Albrecht JK (as a member of the Hepatitis Intervention Therapy Group). *N Engl J Med* 1998;339:1485-1492.
150. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling M-H, Albrecht J (as a member of the Hepatitis Intervention Therapy Group). *N Engl J Med* 1998;339:1493-1499.

151. Is hepatitis G/GB virus-C virus hepatotropic? Detection of hepatitis G/GB virus-C viral RNA in liver and serum. Fan X, Xu Y, Solomon H, Ramrakhiani S, Neuschwander-Tetri BA, **Di Bisceglie AM**. *J Med Virol* 1998;58:160-164.
152. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Fan X, Solomon H, Poulos J, Neuschwander-Tetri BA, **Di Bisceglie AM**. *Am J Gastroenterol* 1999;94:1347-1354.
153. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Bassett SE, **Di Bisceglie AM**, Bacon BR, Sharp RM, Govindarajan S, Hubbard GB, Brasky KM, Lanford RE. *Hepatology* 1999;29:1884-1892.
154. Seroprevalence of viral hepatitis in an elderly nursing home population. Chien NT, Dundoo G, Horani MH, Osmack P, Morley JE, **Di Bisceglie AM**, et al. *J Am Geriatr Soc* 1999;47:1110-1113.
155. Hepatocellular carcinoma not related to hepatitis B virus infection among Alaska natives. Chung Y-H, **Di Bisceglie AM**, McMahon BJ, Lanier AP, Harpster A, Alter MJ, Parkinson AJ, Zanis C. *Internatl J Circumpolar Hlth* 1999;58:208-213.
156. Liver transplantation in patients with chronic hepatitis C and alcoholism. Dhar S, Omran L, Bacon BR, Solomon H, **Di Bisceglie AM**. *Dig Dis Sci* 1999;44:2003-2007.
157. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Brunt EM, Janney CG, **Di Bisceglie AM**, Neuschwander-Tetri BA, Bacon BR. *Am J Gastroenterology* 1999;94:2467-2474.
158. Resolution of chronic delta hepatitis after 12 years of alpha interferon therapy. Lau DT, Kleiner DE, Park Y, **Di Bisceglie AM**, Hoofnagle JH. *Gastroenterology* 1999;117:1229-1233.
159. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, **Di Bisceglie AM**. *J Hepatol* 2000;32:792-797.
160. Delayed recurrence of hepatocellular carcinoma after liver transplantation: Detection of origin by chromosomal analysis. Al-Joundi T, Gibson S, Brunt EM, Shakil O, Lee RS, **Di Bisceglie AM**. *Liver Transplantation* 2000;6:374-375.
161. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multi-center, prospective, randomized, controlled trial. **Di Bisceglie AM**, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt CM, Tamburro C, Tavill AS, Ferguson DR, Krawitt E, Banner B, Bacon BR. *Hepatology* 2000;32:135-138.

162. Histological evaluation of iron in liver biopsies: relationship to *HFE* mutations. Brunt EM, Olynyk JK, Britton RS, Janney CG, **Di Bisceglie AM**, Bacon BR. *Am J Gastroenterol* 2000;95:1788-1793.
163. A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum. Fanson BG, Osmack P, **Di Bisceglie AM**. *J Virol Methods* 2000;89:23-27.
164. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Sponseller CA. Bacon BR. **Di Bisceglie AM**. *Liver Transplantation* 2000;6:715-20.
165. Hepatic α -smooth muscle actin expression in hepatitis C patients before and after interferon therapy. Khan MA, Poulos JE, Brunt EM, Li L, Solomon H, Britton RS, Bacon BR, **Di Bisceglie AM**. *Hepato-Gastroenterology* 2001;48:212-215.
166. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Naeem M, Bacon BR, Mistry B, Britton RS, **Di Bisceglie AM**. *Am J Gastroenterol* 2001;96:2468-2472.
167. Expression of C-MYC binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. Fan X, Solomon H, Schwarz K, Kew MC, Ray RB, **Di Bisceglie AM**. *Dig Dis Sci* 2001;46:563-566.
168. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Schwarz KB, Kew M, Klein A, Abrams RA, Sitzmann J, Jones L, Sharma S, Britton RS, **Di Bisceglie AM**, Groopman J. *Dig Dis Sci* 2001;46:2173-2178.
169. Differential amplification of hypervariable region 1 (HVR1) of hepatitis C virus by partially mismatched primers. Fan X, Lyra AC, Tan D, Xu Y, **Di Bisceglie AM**. *Biochem Biophys Res Comm* 2001;284:694-697.
170. Genetic characterization of hypervariable region 1 in patients chronically infected with genotype 2b hepatitis C virus. Fan X and **Di Bisceglie AM**. *J Med Virol* 2001;64:325-333.
171. Cryoglobulinemia associated with Purtscher's-like retinopathy. Myers JP, **Di Bisceglie AM**, Mann ES. *Am J Ophthalmol* 2001;131:802-4.
172. A 35 year-old woman with progesterone implant contraception and multiple liver masses. Suarez AA, Brunt EM, **Di Bisceglie AM**. *Semin Liver Dis* 2001;21:453-459.
173. Combination of interferon and ribavirin in chronic hepatitis C: Retreatment of nonresponders to interferon. **Di Bisceglie AM**, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. *Hepatology* 33:704-707, 2001.

174. Complement mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C E2 chimeric glycoprotein. Meyer K, Basu A, Przysiecki CT, Lagging LM, **Di Bisceglie AM**, Conley AJ, Ray R. *J Virol* 2002;76:2150-2158.
175. A 32 year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplant. Lyra AC, Brunt EM, Pincus S, **Di Bisceglie AM**. *Seminars in Liver Disease* 2002;22:103-107.
176. Direct evidence for GB virus C/hepatitis G virus (GBV-C, HGV) superinfection: Elimination of resident viral strain by donor strain in a patient undergoing liver transplantation. Fan X, Xu Y, Detre K, **Di Bisceglie AM**. *J Med Virol* 2002;68:76-81.
177. Evidence for probable sexual transmission of the hepatitis G virus. Frey SE, Homan SM, Sokol-Anderson M, Torralba Cayco M, Cortorreal P, Musial C, Mushahwar IK, **Di Bisceglie AM**. *Clin Infect Dis* 2002;34:1033-8.
178. Genetic complexity and serum reactivity of HVR1 quasispecies of hepatitis C virus patients with cirrhosis. Fan X, **Di Bisceglie AM**. *Am J Gastroenterol* 2002;97:1489-1495.
179. Evolution of hepatitis C viral quasispecies after liver transplantation. Lyra AC, Fan X, Ramrakhiani S, Brunt EM, **Di Bisceglie AM**. *Gastroenterology* 2002;123:1485-1493.
180. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, **Di Bisceglie AM**. *Mod Pathol* 2003;16:49-56.
181. Hepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic status. **Di Bisceglie AM**, Lyra AC, Schwarz M, Reddy RK, Martin P, Gores G, Lok ASF, Hussein K, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS; Liver Cancer Network. *Am J Gastroenterol* 2003;98:2060-3.
182. Liver transplantation with hepatitis C virus-infected graft: Interaction between donor and recipient viral strains. Fan X, Lang DM, Xu Y, Lyra AC, Yusim K, Everhart JE, Korber BTM, Perelson AS, **Di Bisceglie AM**. *Hepatology* 2003;38:25-33.
183. Accumulation of B lymphocytes with a naïve, resting phenotype in a subset of hepatitis C patients. Li, J, Mebrador E, **Di Bisceglie AM**, Jacobson IM, Talal AH, Butera D, Rice CM, Chambers TJ, Dustin LB. *J Immunol* 2003;170:3429-3439.
184. Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. Hsia CC, Scudamore CH, **Di Bisceglie AM**, Tabor E. *J Med Virol* 2003;70:20-26.
185. Diversification of hypervariable region 1 of hepatitis C virus after liver transplantation. Fan X, **Di Bisceglie AM**. *J Med Virol* 2003;70:212-218.

186. Infection with hepatitis C virus genotype 4 in the United States. Lyra AC, Ramrakhiani S, Bacon BR, **Di Bisceglie AM**. *J Clin Gastroenterol* 2004;38:68-71.
187. Biliary-venous fistula complicating transjugular intrahepatic portosystemic shunt presenting with recurrent bacteremia, jaundice, anemia and fever. Jawaid Q, Saeed ZA, **Di Bisceglie AM**, Brunt EM, Ramrakhiani S, Varma CR, Solomon S. *Am J Transplantation* 2003;3:1-4.
188. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis: A case report. Brunt EM, **Di Bisceglie AM**. *Human Pathology* 2004;35:509-512.
189. HCV E2 glycoprotein: Mutagenesis of the N-linked glycosylation sites and effects on protein expression and secretion. Slater-Handshy T, Droll D A, Fan X, **Di Bisceglie AM**, and Chambers T. *Virology* 2004;319:36-48.
190. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, **Di Bisceglie AM**, Seneca R, Younossi ZM. *Dig Dis Sci* 2004;49:850-3.
191. Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: Detection by immunostaining. Richart J, Brunt EM, **Di Bisceglie AM**. *Dig Dis Sci* 2002;47:2454-8.
192. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Shiffman ML, **Di Bisceglie AM**, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE, and the HALT-C Trial Group. *Gastroenterology* 2004;126:1015-1023.
193. A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: Does nursing play a role? Strinko JM, **Di Bisceglie AM**, Hoffmann JA. *Issues Mental Health Nurs* 2004;25:715-722.
194. Evolution of the HALT-C trial: Pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, **Di Bisceglie AM**, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE, and the HALT-C Trial Group. *Contr Clin Trials* 2004;25:472-492.
195. Associations among clinical, histologic, immunologic and viral quasispecies measures in advanced chronic hepatitis C: Baseline analysis of the HALT-C trial. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, **Di Bisceglie AM**, et al. *Hepatology* 2005;41:617-625.
196. CD81 binding regions of hepatitis C virus remain conserved after liver transplantation. Lyra AC, Fan X, **Di Bisceglie AM**. *Braz J Infect Dis*. 2004;8:126-132.

197. Screening in liver disease: Report of an AASLD clinical workshop. Adams PC, Arthur MJ, Boyer TD, DeLeve LD, **Di Bisceglie AM**, Hall M, Levin TR, Provenzle D, Seeff L. *Hepatology* 2004;39:1204-1212.
198. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells M, Dustin LB, **Di Bisceglie AM**. *J Virology* 2005;79:3071-3083.
199. Chemoprevention of hepatocellular carcinoma: Use of Tamoxifen in an animal model of hepatocarcinogenesis. **Di Bisceglie AM**, Osmack P, Brunt EM. *J Lab Clin Med* 2005;145:134-138.
200. The safety of intra-abdominal surgery in cirrhotics: A predictive model using the MELD score and pre-operative hemoglobin. Befeler AS, Palmer DE, Hoffman M, Longo W, Solomon H, **Di Bisceglie AM**. *Arch Surg* 2005;140:650-654.
201. Serum alpha-fetoprotein levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: Results from the Halt-C Trial. **Di Bisceglie AM**, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG, Gretch DR and the Halt-C Trial Group. *J Hepatology* 2005;43:434-441.
202. Long term follow up of bone mineral density in patients with primary biliary cirrhosis. **Di Bisceglie AM**, Loyet M, Peters M. *Minerva Med* 2004;95:529-534.
203. Comparison of amplification enzymes for hepatitis C virus quasispecies analysis. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, **Di Bisceglie AM**, Lee WM, Morishima C, Gretch DR and the HALT-C Trial group. *Virology Journal* 2005;2:41.
204. Plasma chemokine levels correlate with the outcome of antiviral therapy in hepatitis C patients. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, **Di Bisceglie AM**, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB. *Blood* 2005;106:1175-1182
205. Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: A case report. Brunt EM, Wolverson MK, **Di Bisceglie AM**. *Semin Liver Dis* 2005;25:230-236.
206. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, **Di Bisceglie AM**, Bacon BR. *Clin Gastroenterol Hepatol* 2005;3:604-609.

207. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Lok ASF, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, **Di Bisceglie AM**, Lee WM, Morgan TR, Dienstag JL, Morishima C and the HALT-C Trial group. *Hepatology* 2005;42:282-293.
208. Diabetic hepatosclerosis: Diabetic microangiopathy of the liver. Harrison SA, Brunt EM, Goodman ZD, **Di Bisceglie AM**. *Arch Pathol Lab Med* 2006;130:27-32.
209. Pharmacokinetics, pharmacodynamics and hepatitis C viral kinetics during antiviral therapy: The null responder. **Di Bisceglie AM**, Fan X, Chambers T, Strinko J. *J Med Virol* 2006;78:446-451.
210. Hepatitis C virus-specific immunity and quasispecies variability at baseline are associated with non-response to antiviral therapy in advanced hepatitis C. Morishima C, Polyak SJ, Ray R, Doherty MC, **Di Bisceglie AM**, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL and the HALT-C Trial group. *J Infect Dis* (in press).
211. Comparison of liver biopsy and non-invasive methods for diagnosis of hepatocellular carcinoma. Bialecki ES, Ezenekwe AM, Brunt EM, Collins BT, Ponder TB, Bieneman BK, **Di Bisceglie AM**. *Clin Gastro Hepatol* 2006;4:361-368.
212. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (PBC). Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo ML, McCashland TM, Zetterman RK, Peters MG, **Di Bisceglie AM**, et al. *Hepatology* 2005;42:1184-1193.
213. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Basu A, Meyer K, Lai KK, Saito K, **Di Bisceglie AM**, Grosso L, Ray RB, Ray R. *Virology* 2006; 349:347-358.
214. The Prevalence and Risk Factors Associated with Esophageal Varices in Subjects with Hepatitis C and Advanced Fibrosis. Sanyal AJ, Fontana RJ, **Di Bisceglie AM**, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, The HALT-C Trial Group. *GI Endoscopy*, 2006 64:855-864
215. HCV RNA detection by TMA during the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, **Di Bisceglie AM**, Lee WM, Dienstag JL, Ghany MG, Gretch DR and the HALT-C Trial Group. *Hepatology* 2006; 44:360-367.
216. Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples. Fan X, Xu Y, **Di Bisceglie AM**. *Biochem Biophys Res Com* 2006;346:1163-1172.

217. Hepatic steatosis in hepatitis C: Comparison of diabetic and non-diabetic patients in the HALT-C Trial. Lok ASF, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, **Di Bisceglie AM**, Lee WM, Morgan TR, Ghany MG, Miroshima C and the HALT-C Trial group. *Clin Gastro Hepatol* 2006;5:245-254.
218. Spontaneous retroperitoneal and rectus muscle hemorrhage as a potentially lethal complication of cirrhosis. **Di Bisceglie AM**, Richart JM. *Liver International* 2006;26:1291-1293.
219. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, **Di Bisceglie AM**, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group. *J Hepatol.* 2007;46:42-431.
220. Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, **Di Bisceglie AM**, Lee WM, Dienstag JL, Gretch DR, and the HALT-C Trial Group. *Gastroenterology* 2007;132:103-112.
221. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Bonkovsky HL, Naishadham D, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, **Di Bisceglie AM**, Ghany MG, Morishima C; HALT-C Trial Group. *Gastroenterology* 2006;131:1440-51.
222. Impact of Disease Severity on Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons from the HALT-C Trial. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok ASF, **Di Bisceglie AM**, Lee WM, Dienstag JL, Ghany MG, Morishima C, and the HALT-C Trial Group. *Hepatology* 2006 44:1675-1684.
223. Separation of near full-length hepatitis C virus quasispecies variants from complex population. Zhou D, Fan X, Tan D, Xu Y, Tavis JE, **Di Bisceglie AM**. *J Virological Methods* 2007;141:220-224
224. Early virologic response after peginterferon alfa-2A plus ribavirin or peginterferon alfa-2b plus ribavirin treatment in patients with chronic hepatitis C. **Di Bisceglie AM**, Ghalib RH, Hamzeh FM, Rustgi VK. *J Viral Hepatitis* 2007;14:721-729.
225. Sequence diversity in the full-length hepatitis C virus coding region correlates with response to therapy. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, **Di Bisceglie AM**, Aurora R, Tavis JE for the Virahep-C Study Group. *J Virol* 2007;81:8211-8224.
226. Telbivudine versus Lamivudine for Patients with HBeAg-positive Chronic Hepatitis B: Results of a Global Phase III Comparative Trial. Lai CL, Gane E, Liaw Y-F, Thongsawat S,

Wang Y, Chen Y, Heathcote J, Rasenack J, Bzowej N, **Di Bisceglie AM**, Zeuzem S, Naoumov N, Moon YM, Goodman Z, Chao G, Fielman B, Brown N and the GLOBE Study Group. *New Engl J Med* 2007;357:2576-2588.

227. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Brunt EM, Walsh SN, Hayashi PH, LaBundy J, **Di Bisceglie AM**. *Liver International* 2007;27:662-671.
228. Differences between Caucasian, African American and Hispanic patients with primary biliary cirrhosis in the United States. Peters MG, **Di Bisceglie AM**, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia-Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B. *Hepatology* 2007;46:769-775.
229. Herbal Product Use by Persons Enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok ASF, **Di Bisceglie AM**, Lee WM, Ghany MG and the HALT-C Trial Group. *Hepatology* 2008;47:605-612.
230. Cost-effectiveness of entecavir versus lamivudine in HBeAg-positive chronic hepatitis B based on a 2-year clinical trial. Veenstra DL, Iloeje JH, Sullivan SD, Tafesse E, Clark L, **Di Bisceglie AM**, Kowdley KV, Gish RG. *Pharmacoeconomics* 2007;25:963-977.
231. Prediction of clinical outcomes in primary Biliary cirrhosis by serum enhanced liver fibrosis assay. Mayo M, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew M, Butsch R, Luketic V, Peters M, **Di Bisceglie AM** et al. *Hepatology* 2008;48:1549-1557.
232. Incidence Of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Lok AS, Seeff LB, Morgan TR, **Di Bisceglie AM**, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman and the HALT-C Trial Group. *Gastroenterology* 2009;136:138-148.
233. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, MacPhail P, Sanne I, **Di Bisceglie A**. *S Afr Med J* 2008;98:541-544.
234. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, **Di Bisceglie AM**, MacPhail P, Sanne I, Kew M. *J Inf Dis* 2009;193:488-492 (Epub 2008 Dec 9).
235. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon a-2a and ribavirin. Fried MW, Jensen D,

- Rodriguez-Torres M, Nyberg L, **Di Bisceglie AM**, Morgan T, Pockros P, Lin A, Cupelli L, Duff F, Wang K, Nelson D. *Hepatology* 2008;48:1033-1043.
236. Clinical, Virologic, Histologic, and Biochemical Outcomes after Successful HCV Therapy: a 5 year follow-up of 150 patients. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, **Di Bisceglie AM**. *Hepatology* 2009;49:729-738.
237. Prolonged Therapy Of Advanced Chronic Hepatitis C With Low Dose Peginterferon. **Di Bisceglie AM**, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL for the HALT-C Trial Group. *N Engl J Med* 2008;359:2429-2441.
238. Evidence for action of ribavirin through the hepatitis C virus RNA polymerase. Cannon NA, Donlin MJ, Mayes LM, Lyra AC, **Di Bisceglie AM**, Tavis JE. *J Viral Hepatitis* 2009;16:595-604.
239. Lack of Association between Genotypes and Subtypes of HCV and Occurrence of Hepatocellular Carcinoma in Egypt. Ryu S, Fan X, Xu Y, Elbaz T, Zekri A-RN, Abdelaziz AO, **Di Bisceglie AM**. *J Med Virol* 2009;81:844-847.
240. Baseline characteristics and early on-treatment response predict the outcomes of two years telbivudine treatment of chronic hepatitis B. Zeuzem S, Gane E, Liaw Y-F, Lim SG, **Di Bisceglie AM** et al. *J Hepatol* 2009;51:11-20.
241. Evolution of Hepatic Steatosis in Patients with Advanced Hepatitis C: Results From The Halt-C Trial. Lok AS, Everhart JE, Chung RT, Kim H-Y, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, **Di Bisceglie AM**, Bonkovsky HL, Ghany MG, Morishima C and the HALT-C Trial Group. *Hepatology* 2009;49:1828-1837.
242. Mutations in the Hepatitis C Virus Core Gene Are Associated with Advanced Liver Disease and Hepatocellular Carcinoma. Fishman S, **Di Bisceglie AM**, Branch A and others. *Clin Cancer Res Clin Cancer Res* 2009;15:3205-3213.
243. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-a2b. A randomized trial. Jensen DM, Marcellin P, Freilich B, Andreone P, **Di Bisceglie AM** et al. *Ann Intern Med* 2009;150:528-540.
244. Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Welzel TM, Morgan TR, Bonkovsky HL, Naishadam D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, **Di Bisceglie AM** et al. *Hepatology* 2009;49:1847-1858.

245. Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy On Clinical Outcomes in the HALT-C Trial. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, **Di Bisceglie AM**, Bonkovsky HL, Ghany MG and the HALT-C Trial Group. *Gastroenterology* 2009;137:1986-1994.
246. Detection and Quantification of Hepatitis C Virus by MultiCode-RTx Real-Time PCR Targeting the 3'-Untranslated Region. Mulligan EK, Germer JJ, Arens MQ, D'Amore KL, **Di Bisceglie AM**, Ledeboer NA, Moser MJ, Newman AC, O'Guin AK, Olivo PD, Podzorski DS, Vaughan KA, Yao JD, Elagin SA and Johnson SC. *J Clin Microbiol* (2009 Jun 17, Epub ahead of print).
247. Coffee Intake Is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, **Di Bisceglie AM**, Bonkovsky1 HL, Hoefs JC, Dienstag JL, Morishima1 C, Abnet CC, Sinha R and the HALT-C Trial Group. *Hepatology* 2009;50:1360-1369.
248. High Diversity of Hepatitis C Viral Quasispecies is Associated with Early Virological Response in Patients undergoing Antiviral Therapy. Fan X, Mao Q, Zhou D, Lu Y, Xing J, Xu Y, Ray S, **Di Bisceglie AM**. *Hepatology* 2009;50:1765-1772.
249. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Wang M, Long R, Comunale MA, Junaidi O, Marrero J, **Di Bisceglie AM**, Block T, Mehta A. *Cancer Epidemiol Biomarkers Prev* 2009;18:1914-1921.
250. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2 and NS5a. Xu Z, Fan X, Xu Y, **Di Bisceglie AM**. *J Virol* 2008;82:9417-9424.
251. Procarbazine Hepatotoxicity: Case Report and Review of the Literature. Fesler MJ, Becker-Koepke S, **Di Bisceglie AM**, Petruska PJ. *Pharmacotherapy* 2010;30:540.
252. Des- γ -carboxy Prothrombin and α -fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Lok AS, Sterling R, Everhart J, Wright E, Hoefs J, **Di Bisceglie AM**, Morgan T, Kim H-Y, Lee W, Bonkovsky H, Dienstag J. *Gastroenterology* 2010;138:493-502.
253. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Singal AG, Volk ML, Jensen J, **Di Bisceglie AM**, Schoenfeld PS. *Clin Gastro Hepatol* 2010;8:280-288.
254. Predicting Clinical and Histological Outcomes Based on Standard Laboratory Tests In Advanced Chronic Hepatitis C. Ghany MG, Lok ASF, Everhart JE, Everson GT, Lee WM,

- Curto TM, Wright EC, Stoddard AM, Sterling RK, **Di Bisceglie AM** et al for the HALT-C Trial Group. *Gastroenterology* 2010;138:136-146.
255. Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients. Donlin M, Cannon NA, Aurora R, Li J, Wahed AS, **Di Bisceglie AM**, Tavis JE. *PLoS One* 2010 ;5(2): e9032. doi:10.1371/journal.pone.0009032
256. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Snow KK, Bonkovsky HL, Fontana RJ, Kim H-Y, Sterling RK, **Di Bisceglie AM**, Morgan TR, Dienstag JL, Ghany MG. *Alimentary Pharmacology & Therapeutics* 2010;31: 719-734.
257. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, **Di Bisceglie AM**, Szabo G, Morgan TR, Everhart JE. *Gastroenterology* 2010;138:2321-2331.
258. Enhanced Protocol for Determining the 3' Terminus of Hepatitis C Virus. Zhang X, Fan X, Xu Y and **Di Bisceglie AM**. *J Virol Method* 2010;167:158-164.
259. Telaprevir for previously treated chronic HCV infection. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, **Di Bisceglie AM**. *N Engl J Med* 2010;362:1292-1303.
260. Markedly Elevated Serum CA 19-9 Levels in Association With a Benign Biliary Stricture Due to Primary Sclerosing Cholangitis. Murray MD, Burton FR, **Di Bisceglie AM**. *J Clin Gastroenterol* 2007;41:115–117.
261. Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults. Frey SE, **Di Bisceglie AM**, Abrignani S, Ray R, Houghton M. *Vaccine* 2010; 28:6367-73.
262. Outcome of Sustained Virological Responders with Histologically Advanced Chronic Hepatitis C. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, **Di Bisceglie AM**, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, and the HALT-C Trial Group. *Hepatology* 2010;52:833-44.
263. Linkage Specific Fucosylation of Alpha-1-Antitrypsin in Liver Cirrhosis and Cancer Patients: Implications for a Biomarker of Hepatocellular Carcinoma. Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P, **Di Bisceglie AM** et al. *PLoS ONE* 2010;5: e12419. doi:10.1371/journal.pone.0012419.

264. Complication Rate of Percutaneous Liver Biopsies Among Persons with Advanced Chronic Liver Disease in the HALT-C Trial. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, **Di Bisceglie AM**, Bonkovsky HL, Dienstag JL, and the HALT-C Trial Group. *Clin Gastroenterol Hepatol* 2010;8:977-83.
265. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/Ribavirin in chronic hepatitis C. Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, **Di Bisceglie AM**. *Hepatology* 2010;52:1906-1914.
266. Maintenance Peginterferon Therapy and Other Factors Associated with Hepatocellular Carcinoma in Patients with Advanced Hepatitis C. Lok AS, Everhart JE, Wright EC, **Di Bisceglie AM**, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, HALT-C Trial Group. *Gastroenterol* 2011;140:840-849.
267. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. **Di Bisceglie AM**, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; for the HALT-C Trial Group. *Hepatology*. 2011;53:1100-1108.
268. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. Jacobson IM, McHutchison JG, Dusheiko G, **Di Bisceglie AM** et al for the ADVANCE Study Team. *N Engl J Med* 2011;364:2405-2416.
269. A prospective study of the rate of progression in compensated histologically advanced chronic hepatitis C. Dienstag JL, Ghany MG, Morgan TR, **Di Bisceglie AM**, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. *Hepatology*. 2011;54:396-405.
270. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Lok AS, Everhart JE, **Di Bisceglie AM**, Kim, H-Y, Hussain M, Morgan TR and the HALT-C trial group. *Hepatology* 2011;54:434-442.
271. Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation. Wang W, Lin J, Xu Y, Brunt EM, Fan X, **Di Bisceglie AM**. *Biochem Biophys Res Comm* 2011;414:148-152.
272. The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. Zhang X, Ryu SH, Xu Y, Elbaz T, Zekri A-RN, Abdelaziz AO, Abdel-Hamid M, thiers V, Elena SF, Fan X, **Di Bisceglie AM**. *J Clin Virol* 2011;52:333-338.
273. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, **Di**

- Bisceglie AM**, Dienstag JL, Lok AS and the HALT-C Trial group. *Am J Gastroenterol* 2012;107:64-74.
274. Hepatitis C Virus Proteins Inhibit C3 Complement Production. Mazumdar B, Kim H, Meyer K, Bose SK, **Di Bisceglie AM**, Ray RB, Ray R. *J Virol.* 2012, 86:2221-8.
275. Morishima, C., **Di Bisceglie, A.M.**, Rothman, A.L., Bonkovsky, H.L., Lindsay, K.L., Lee, W.M., Koziel, M.J., Fontana, R.J., Kim, H.Y., and Wright, E.C. and the HALT-C Trial Group. Antigen-Specific Lymphocyte Proliferation Decreases Over Time in Advanced Chronic Hepatitis C, *Journal of Viral Hepatitis* 2012;19:404.
276. Potentially Curative Treatment in Patients with Hepatocellular Cancer—Results from the Liver Cancer Research Network. Kanwal, Fasiha; Befeler, Alex; Marrero, Jorge; Chari, Ravi; Afdhal, Nid; Morgan, Timothy; Robert, Lewis; Mohanty, Smruti; Schwartz, Jonathan M; Van Thiel, David; **Di Bisceglie, Adrian**; Li, Juan; Zeringue, Angeliq . *Ali Pharm Ther* (in press).
277. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. *Am J Gastroenterol* June 2012 [Epub ahead of print]

MANUSCRIPTS SUBMITTED FOR PUBLICATION

1. Hepatocellular Adenomas in a U.S. Center: Clinical-Pathologic Correlations Utilizing A Recently Proposed Classification. Kumari R, Pinsky BW, Bioulac-Sage P, Balabaud C, **Di Bisceglie AM**, Bacon BR, Brunt EM.
2. Hepatocellular Carcinoma Biomarker GP73: Effects of Interleukin-6 Family Cytokines and Interferon- α in Human Hepatic Cells and in People. Liang H, Block TM, Wang M, Long R, Hafner J, Mehta AS, **Di Bisceglie AM**, Gish R, Norton PA..

REVIEWS, EDITORIALS, AND BOOK CHAPTERS:

1. Cirrhosis and chronic pancreatitis in alcoholics. (Editorial). **Di Bisceglie AM** and Segal I. *J Clin Gastroenterol* 1984;6:199-200.
2. Biliary obstruction due to chronic pancreatitis. **Di Bisceglie AM** and Segal I. *Tropic Gastroenterol* 1984;5:29-34.
3. Hepatitis B virus infection and hepatocellular carcinoma. Etiologic relationship and clinical implications. **Di Bisceglie AM** and Hoofnagle JH. In, DeVita VT, Hellman S, Rosenberg SA (eds). *Cancer: Principles and practice of Oncology* (updated). J.B. Lippincott Co. 1987;1-10.

4. Management of post-transfusion hepatitis. Hoofnagle JH, **Di Bisceglie AM**, Lisker-Melman M, Kassianides C, Martin P. *Trans Med Rev* 1988;2:215-220.
5. Hepatocellular carcinoma. **Di Bisceglie AM**, moderator. Proceedings of NIH Combined Clinical Staff Conference. *Ann Int Med* 1988;108:390-401.
6. Treatment of chronic type B hepatitis. **Di Bisceglie AM**, Hoofnagle JH. *Cancer Detect Prevent* 1989;14:291-294.
7. Interferon therapy of complicated hepatitis B infection. **Di Bisceglie AM**. *Semin Liver Dis* 1989;9:254-258.
8. Interferon therapy of chronic type C hepatitis. Hoofnagle JH, **Di Bisceglie AM**. *Semin Liver Dis* 1989;9:259-263.
9. Diagnosis of hepatitis delta virus infection (Editorial). **Di Bisceglie AM**, Negro F. *Hepatology* 1989;10:1014-1016.
10. Antiviral therapy of viral hepatitis. Hoofnagle JH, **Di Bisceglie AM**. *Antiviral Agents and Viral Diseases of Man*, 3rd ed. 1990;415-459.
11. Treatment of chronic non-A, non-B (type C) hepatitis. Hoofnagle JH, **Di Bisceglie AM**. In, Shikata T, Purcell RH, Uchida T, eds. *Viral hepatitis C, D, E*. Elsevier, Amsterdam 1991;151-156.
12. Therapy of chronic hepatitis C with alpha interferon (Editorial). The answer? or More Questions? **Di Bisceglie AM**, Hoofnagle JH. *Hepatology* 1991;13:601-603.
13. Serologic diagnosis of acute and chronic viral hepatitis. Hoofnagle JH, **Di Bisceglie AM**. *Semin Liv Dis* 1991;11:73-83.
14. Chronic viral hepatitis and hepatocellular carcinoma. **Di Bisceglie AM**. In, Tabor E, **Di Bisceglie AM**, Purcell RH, eds. *Hepatocellular Carcinoma in North America*. Portfolio Publishing. Houston 1991;127-138.
15. Delta hepatitis. **Di Bisceglie AM**. In, Perrillo RP, ed. *Hepatitis. Viral and drug induced*. National Health Labs. La Jolla. 1991;19-26.
16. Therapy of chronic delta hepatitis: An overview. Hoofnagle JH, **Di Bisceglie AM**. In, Bonino F, Taylor J, Hadziyannis S, eds. *Hepatitis Delta Virus*. Wiley-Liss, New York 1993;337-343.
17. Natural history of hepatitis D virus. Conjeevaram H, **Di Bisceglie AM**. In, Zuckerman AJ, Thomas HC, eds. *Viral hepatitis (1st ed)*, Churchill Livingstone. 1993;341-350.

18. Epidemiology and diagnosis of hepatitis D virus. **Di Bisceglie AM.** In, Zuckerman AJ, Thomas HC, eds. *Viral hepatitis* (1st ed), Churchill Livingstone 1993;351-362.
19. Metabolic diseases of the liver. Fried MW, **Di Bisceglie AM.** In, Rustgi VK, Van Thiel DH, eds. *The Liver in Systemic Disease.* Raven Press, New York 1993;167-189.
20. Alpha interferon therapy for chronic viral hepatitis: From bench to approval. **Di Bisceglie AM,** Hoofnagle JH. In, Strand V, ed. *Biologic Agents in Autoimmune Diseases.* Arthritis Foundation, Atlanta 1994;65-69.
21. Interferon therapy of chronic viral hepatitis. **Di Bisceglie AM.** *N Engl J Med* 1994;330:137-138 .
22. Viral hepatitis and hepatocellular carcinoma. Sallie R, **Di Bisceglie AM.** In, Martin P, Friedman L, eds. *Clin Gastroenterol* 1994;23:567-579.
23. Interferon therapy for chronic viral hepatitis (Editorial). **Di Bisceglie AM.** *N Engl J Med* 1994;350:137-138.
24. Extra-hepatic manifestations of chronic viral hepatitis. Shakil OA, **Di Bisceglie AM.** 'L' Internista' 1994;2:139-144.
25. Hepatitis C and hepatocellular carcinoma. **Di Bisceglie AM.** *Semin Liver Dis* 1995;15:64-69.
26. New treatments for chronic hepatitis B. **Di Bisceglie AM.** In, Arroyo V, Bosch J, Rodes J, eds. *Treatments in Hepatology.* Masson, S.A., Barcelona 1995;203-206.
27. Management of chronic viral hepatitis in children. Conjeevaram H, **Di Bisceglie AM.** *J Ped Gastro Nutr* 1995;20:365-375.
28. Long-term outcome of alpha interferon therapy for chronic hepatitis B. **Di Bisceglie AM.** *J Hepatol* 1995;22(Suppl):65-67.
29. Chronic hepatitis B: Hope for decreasing its impact. **Di Bisceglie AM.** *Postgraduate Medicine* 1995;98:99-106.
30. Liver transplantation for hepatitis C: The promise and the challenge. **Di Bisceglie AM.** *Hepatology* (Editorial) 1995;22:660-662.
31. New hepatitis viruses: Adding to the alphabet soup (Editorial). **Di Bisceglie AM.** *Viral Hepatitis Reviews* 1995;1:3-5.

32. Tumors of the liver. **Di Bisceglie AM**, Buetow PC. In, Maddrey WC, Feldman M, eds. Gastroenterology and Hepatology: The Comprehensive Visual Reference (The Liver) 1995;1:13.2-13.13.
33. Tumors of the liver. **Di Bisceglie AM**. In, Bone RC, ed. Current Practice of Medicine 1996;4:15.1-15.8.
34. Chronic viral hepatitis. **Di Bisceglie AM**, Hoofnagle JH. In, Zakim D, Boyer T, eds. Hepatology, 3rd edition. Philadelphia 1996;1299-1329.
35. Liver. **Di Bisceglie AM**, Tabor E. Cancer Rates and Risks 4th edition. National Institutes of Health, National Cancer Institute 1996;155-157.
36. Interpreting serologic tests for hepatitis C virus infection: balancing cost and clarity. Long GS, Bacon BR, **Di Bisceglie AM**. Clev Clin J Med 1996;63:264-268.
37. Hepatitis G virus infection -- a work in progress (Editorial). **Di Bisceglie AM**. Ann Intern Med 1996;125:772-773.
38. Thymus-derived peptides for chronic viral hepatitis: Have they fulfilled their promise? (Editorial) **Di Bisceglie AM**. Dig Dis 1996;14:331-333.
39. Hepatitis D virus. **Di Bisceglie AM**. In, Willson R, ed. Viral Hepatitis, Marcel Dekker, New York, 1996;217-238.
40. The treatment of chronic viral hepatitis. Hoofnagle JH, **Di Bisceglie AM**. N Engl J Med 1997;347-356.
41. Hepatitis C. **Di Bisceglie AM**. The Lancet 1998;351:351-55.
42. Hepatitis C: Clinical aspects and therapy. **Di Bisceglie AM**, Rakela J. In, Rizzetto M, ed. Viral Hepatitis and Liver Diseases; Proceedings of the IXth Triennial Int'l Symposium on Viral Hepatitis and Liver Diseases. 1997;916-918.
43. Consultants and Comments: Preventing sexual transmission of hepatitis C. **Di Bisceglie AM**. Consultant 1997, p. 1774.
44. Hepatic tumors. **Di Bisceglie AM**. In, Friedman LS, Keefe E, eds. Handbook of Liver Diseases. Churchill Livingstone, Edinburgh, 1998;361-372.
45. Management of chronic viral hepatitis. **Di Bisceglie AM**, Hoofnagle JH. In, **Di Bisceglie AM**, Bacon BR, eds. Liver Disease: Diagnosis and Management. Churchill Livingstone, New York, 1999, pp. 98-106.

46. Consensus³: The coming of age of hepatitis C. **Di Bisceglie AM** (Editorial). *Viral Hepatitis Reviews* 1997;3:201-202.
47. Hepatitis C and hepatocellular carcinoma. **Di Bisceglie AM**. *Hepatology* 1997;26:34S-38S.
48. Hepatitis G virus infection around the world: Prevalence, mode of transmission risk factors and association with hepatitis. Shah D, Mitra AK, **Di Bisceglie AM**. *Viral Hepatitis Reviews* 1997;3:179-188.
49. Diagnosis and treatment of hepatocellular carcinoma. **Di Bisceglie AM**. *Gastroenterology* 1997;113:1807-1809.
50. The liver mass--clinical. **Di Bisceglie AM**. In, Bloomer JR, Goodman ZD, Ishak KG. *Clinical and Pathological Correlations in Liver Disease: Approaching the Next Millennium* 1998;97-102.
51. Natural history of hepatitis D virus. Conjeevaram H, **Di Bisceglie AM**. In, Zuckerman AJ, Thomas HC, eds. *Viral hepatitis (2nd Edition)*. Churchill Livingstone 1998;379-385.
52. Epidemiology and diagnosis of hepatitis D virus. **Di Bisceglie AM**. In, Zuckerman AJ, Thomas HC, eds. *Viral hepatitis (2nd Edition)*. Churchill Livingstone 1998;371-378.
53. Hepatocellular carcinoma. **Di Bisceglie AM**, Carithers Jr. RL, Gores GJ. *Hepatology* 1998;28:1161-1165.
54. Hepatocellular carcinoma. Tabor E, **Di Bisceglie AM**. *Clinics in Liver Disease* 1999;3:327-348.
55. Malignant neoplasms of the liver. **Di Bisceglie AM**. In, Schiff ER, Maddrey WC, Sorrell M, eds. *Schiff's Diseases of the Liver (8th edition)*. Lippincott-Raven 1999;1281-1303.
56. Viral Hepatitis. **Di Bisceglie AM**. In, Dolin R, Masur H, Saag M, eds. *AIDS Therapy*. Churchill Livingstone 1999;516-529.
57. Management of tumors of the liver. Stribling R, Martin P, **Di Bisceglie AM**. In, Wolfe MM, ed. *Therapy of Digestive Disorders*, 1999; Chapter 102, pp. 901-904.
58. Tumors of the liver. **Di Bisceglie AM**. *Current Practice Medicine* 1999;2:109-116.
59. Iron and viral hepatitis. **Di Bisceglie AM**. In, Arroyo V, Bosch J, Bruguera M, Rodes J, Sanchez Tapias JM. *Treatment of Liver Diseases*. Masson, Barcelona. 1999, pp. 307-310.
60. Viral Hepatitis. **Di Bisceglie AM**. In, *Digestive Disease Self-Evaluation Program (DDSEP) for the American Gastroenterological Association*, 1999.

61. Hepatitis B. Befeler AS and **Di Bisceglie AM**. In, Infectious Disease Clinics of North America 1999;14:617-632.
62. Management of tumors of the liver. **Di Bisceglie AM** and Richart JM. In, Wolfe MM, ed. Therapy of Digestive Disorders: A Companion to Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 1999, pp. 421-428.
63. Hepatitis C - Virology and future antiviral targets. **Di Bisceglie AM**. Am J Med 1999; 107(6B):45S-48S.
64. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. **Di Bisceglie AM**. Am J Med 1999;107(6B):53S-56S.
65. **Di Bisceglie AM**: Tumors of the Liver. Current Practice of Medicine [serial online: <http://praxis.md>]. 2000 Jan; 3(1).
66. Tumors of the liver. **Di Bisceglie AM**, Buetow PC. In, Maddrey WC, Feldman M, eds. Gastroenterology and Hepatology: The Comprehensive Visual Reference (The Liver, 2nd Edition), 2000, pp. 13.1-13.14.
67. The 10th triennial meeting on viral hepatitis and liver diseases, Atlanta, 9 to 13 April 2000: A personal perspective. **Di Bisceglie AM**. Viral Hepatitis Reviews 2000;6:1-3.
68. Hepatocellular carcinoma. **Di Bisceglie AM**. Clin Perspectives in Gastro 2000;3:33-39.
69. Natural history of hepatitis C: Its impact on clinical management. **Di Bisceglie AM**. Hepatology 2000;31:1014-1018.
70. New developments in hepatocellular carcinoma. **Di Bisceglie AM**. Online presentation: www.medscape.com/Medscape/CNO/2000/AASLD/Story for the American Association for the Study of Liver Diseases 51st Annual Meeting and Postgraduate Course, 2000.
71. Hepatitis and hepatocellular carcinoma. **Di Bisceglie AM**. In Hepatitis C. Academic Press, 2000, pp. 265-275.
72. Hepatitis C – evolving therapeutic strategies. **Di Bisceglie AM**. In, Boyer JL, Blum HE, Maier K-P, Sauerbruch T, Stalder GA, eds. Liver Cirrhosis and Its Development. Falk Symposium 115, 2001, pp. 156-160.
73. Liver Tumors. **Di Bisceglie, AM**. In, Clinics in Liver Disease, Guest Editor. W.B. Saunders Co., Philadelphia. Vol. 5, February 2001.
74. Preventive strategies for chronic liver disease (editorial). **Di Bisceglie AM**. American Family Physician 2001;64:1515-1516.

75. Liver diseases. Instructional pamphlet written for SLUCare/Tenet, 2001. **Di Bisceglie AM.**
76. An error rationalized is still a mistake. **Di Bisceglie AM.** Lancet 2002;360:1688 (commentary).
77. SEN and sensibility: Interactions between newly discovered and other hepatitis viruses? **Di Bisceglie AM.** Lancet 2001;358:1925-1926 (commentary).
78. Compartmentalization of hepatitis C viral quasispecies. Fan X, Castro-Lyra A, **Di Bisceglie AM.** In *Therapies for Viral Hepatitis*. Schinazi RF, Rice C, and Sommadossi J-P (eds). Elsevier Science, The Netherlands, January 2002, pp. 123-130.
79. Treatment in patients with normal ALT and/or minimal histologic lesions. Lyra AC and **Di Bisceglie AM.** In, Textbook of Viral Hepatitis, 1st edition. São Paulo, Editora Atheneu, 2002, p. 158-67D.
80. Cystic and nodular diseases of the liver. **Di Bisceglie AM** and Befeler AS. In, Schiff's Diseases of the Liver, Ninth Edition. Schiff ER, Sorrell MF, Maddrey WC (eds). Lippincott Williams and Wilkins. Philadelphia. pp. 1149-1168.
81. Treatment of hepatocellular carcinoma. In, Viruses and Liver Cancer. **Befeler A and Di Bisceglie AM.** Tabor E (ed), Elsevier Science B.V., The Netherlands, 2002, pp. 161-172.
82. Viral Hepatitis. **Di Bisceglie AM.** In, Digestive Disease Self-Evaluation Program (DDSEP II) for the American Gastroenterological Association, 2002.
83. Hepatocellular carcinoma: Diagnosis and treatment. Befeler AS, **Di Bisceglie AM.** Gastroenterology 2002;122:1609-1619.
84. What is the optimal therapy for chronic hepatitis B? Lyra AC, **Di Bisceglie AM.** Minerva Medica 2002;96:431-434.
85. Combination therapy for hepatitis B. **Di Bisceglie AM.** Gut 2002;50:443-446.
86. Epidemiology and clinical presentation of hepatocellular carcinoma. **Di Bisceglie AM.** JVIR 2002;13:S169-S171.
87. Optimal therapy of hepatitis C. **Di Bisceglie AM** and Hoofnagle JH. Hepatology 2002;36:S121-S127.
88. Hepatitis C – Current diagnosis and emerging treatment options. **Di Bisceglie AM.** Thomson PDR, Montvale, NJ. 2003. pp. 1 – 16.
89. Tumors of the liver. **Di Bisceglie AM.** In, Maddrey WC and Feldman M, eds. Atlas of the Liver, 3rd Edition. Current Medicine, Philadelphia, 2003, pp. 287-301.

90. Hepatitis and hepatocellular carcinoma. **Di Bisceglie AM.** In, Buti M, Esteban R, eds. Viral Hepatitis. Accion Medica SA, Madrid, 2003, pp. 133-138.
91. Viral Hepatitis. **Di Bisceglie AM.** In, Digestive Disease Self-Evaluation Program (DDSEP III) for the American Gastroenterological Association. Chapter 13, pp. 271-288, 2004.
92. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Harrison SA and **Di Bisceglie AM.** Drugs 2003;63:2379-2394.
93. What every hepatologist should know about endocrinology: Obesity, diabetes, and liver disease (editorial). **Di Bisceglie AM.** Gastroenterology 2004;126:604-606.
94. Screening in liver disease. Adams PC, Arthur MJ, Blanck Heidi, Boyer TD, DeLeve LD, **Di Bisceglie AM,** Hall M, Levin TR, Provenzale D, Seeff L. Hepatology 2004;39:1204-1212.
95. Hepatic tumors. **Di Bisceglie AM.** In, Friedman LS, Keeffe EB, eds. Handbook of liver disease, second edition. Churchill Livingstone, Philadelphia, 2004, pp. 339-348.
96. Molecular biology and clinical implication of hepatitis C virus. Lyra AC, Fan X, **Di Bisceglie AM.** Brazilian J Med Biol Res 2004;37:691-695.
97. New therapeutic strategies in hepatitis C. **Di Bisceglie AM,** McHutchison J, Rice CM. Hepatology 2002;35:224-231.
98. Foreword: Advances in the treatment of chronic hepatitis C. **Di Bisceglie AM.** Seminars in Liver Disease 1999;19:1-2.
99. The unmet challenge of hepatitis C. **Di Bisceglie AM** and Bacon BR. Scientific American 1999 (Oct.):58-63. (reprinted in Infectious Disease. A Scientific American Reader. University of Chicago Press, Chicago. 2008. pp. 47-57).
100. Issues in screening and surveillance for hepatocellular carcinoma. **Di Bisceglie AM.** Gastroenterology 2004;127:S104-S107..
101. Screening for hepatocellular carcinoma: Being old is not all bad. **Di Bisceglie AM.** Am J Gastroenterol 2004;99:1470-6.
102. Screening for hepatocellular carcinoma. Bialecki E, **Di Bisceglie AM.** In, McHutchison J, ed. Management issues in hepatitis C infection. Science Press. London. 2004. pp. 118-121.
103. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, **Di Bisceglie AM.** Ann Intern Med 2004;141:715-17.

104. Diagnosis of hepatocellular carcinoma. Bialecki ES, **Di Bisceglie AM.** (2005) *HPB* 2005;7:26-34.
105. Clinical presentation and natural course of hepatocellular carcinoma. Bialecki ES, **Di Bisceglie AM.** *European J Gastro Hepatol* 2005;17:485-489.
106. Screening for hepatocellular carcinoma. Bialecki E and **Di Bisceglie AM.** In, *Handbook of Management Issues in Hepatitis C.* 2005, pp. 119-130.
107. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: Presentation, screening, prevention, and treatment of hepatocellular carcinoma – Part I. Hayashi PH, **Di Bisceglie AM.** *Med Clin N Am* 2005;89:345-370.
108. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: Presentation, screening, prevention, and treatment of hepatocellular carcinoma – Part II. Hayashi PH, **Di Bisceglie AM.** *Med Clin N Am* 2005;89:371-390.
109. Liver transplantation for hepatocellular carcinoma. Befeler AS, Hayashi PH, **Di Bisceglie AM.** *Gastroenterology* 2005;128:1752-1764.
110. Pretransplant treatments for hepatocellular carcinoma: Do they improve outcomes? **Di Bisceglie AM.** *Liver Transplant* 2005;11:S10-S13.
111. Imaging of the liver. Bieneman BK, **Di Bisceglie AM.** In, *Comprehensive Clinical Hepatology*, second edition. Mosby Elsevier, Philadelphia, 2006, pp.123-136.
112. Hepatitis C. **Di Bisceglie AM.** In, *Comprehensive Clinical Hepatology*, second edition. Mosby Elsevier. Philadelphia, 2006, pp. 235-248.
113. The progression of hepatitis B- and C- infectious to chronic liver disease and hepatocellular carcinoma: Presentation, diagnosis, screening, prevention and treatment of hepatocellular carcinoma. Hayashi PH, **Di Bisceglie AM.** *Infect Dis Clinic N Am* 2006;20:1-17.
114. Tumors of the liver. **Di Bisceglie AM.** In, Feldman M, Maddrey W, eds. *Atlas of the Liver.* Fourth Edition. Springer. Philadelphia, 2006. pp. 327-342.
115. Nodular and cystic lesions. **Di Bisceglie AM,** Befeler AS. In, *Schiff's Diseases of the Liver*, tenth edition. Lippincott Williams & Wilkins. Philadelphia. 2007. pp. 1231-1251.
116. Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA. **Di Bisceglie AM,** Befeler AS. *Hepatology Research* 2007;37:S182-S184.
117. Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA. **Di Bisceglie AM,** Befeler AS. *Hepatology Research* 2007;37(suppl 2):S251-S253.

118. Aging liver and hepatitis. Junaidi O, **Di Bisceglie AM**. Clin Geriatr Med 2007;23:889-903.
119. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Kim WR, Flamm SL, **Di Bisceglie AM**, Bodenheimer HC. Hepatology 2008;47:1363-1370.
120. Liver and biliary diseases. **Di Bisceglie AM**. in, Schmitz PG, Martin KJ, eds. Internal Medicine. Just the Facts. McGraw Hill. 2008. New York. pp. 338-342.
121. Diseases of the pancreas. **Di Bisceglie AM**. in, Schmitz PG, Martin KJ, eds. Internal Medicine. Just the Facts. McGraw Hill. 2008. New York. pp. 343-347.
122. Cancer of the liver. Bartlett DL, **Di Bisceglie AM**, Dawson LA. in, DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. Wolters Kluwer/Lippincott Williams and Wilkins. Philadelphia. 2008. pp. 1129-1156.
123. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet, **Di Bisceglie AM**, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwakar J, Gores GJ for the Panel of Experts in HCC-Design Clinical Trials. J Natl Cancer Inst 2008;100:698-711.
124. Clinical decisions. Management of incidental hepatitis C virus infection. HCV therapy with peginterferon and ribavirin. **Di Bisceglie AM**. N Engl J Med 2009;360:1904-5.
125. Hepatitis B and hepatocellular carcinoma. **Di Bisceglie AM**. Hepatology 2009;49:S56-S60.
126. HBV/HIV Co-Infection Among South African Patients Receiving Anti-Retroviral Therapy. **Di Bisceglie AM**, Maskew M, Schulze D, Reyneke A, Firnhaber C. Antiviral Ther 2010;15(3 Pt B):499-503. PubMed PMID: 20516571.
127. RT-PCR amplification and cloning of large viral sequences. Fan X, **Di Bisceglie AM**. In, Nicola King (ed). RT-PCR protocols: second Edition. Methods in Molecular Biology, Vol 630. p. 130-149.
128. Tumors and cysts of the liver. **Di Bisceglie AM**, Befeler AS. In, Feldman M, Friedman LS, Brandt LJ, eds. Sleisinger and Fordtran's Gastrointestinal and Liver Disease. Ninth Edition. Saunders Elsevier. Philadelphia 2010. pp. 1569-1592.
129. Tavis JE, Donlin MJ, Aurora R, Fan X, and **Di Bisceglie AM**. Prospects for personalizing antiviral therapy for HCV with pharmacogenetics. Genome Medicine 2011;3:8.
130. Cancer of the Liver. Bartlett DL, **Di Bisceglie AM**, Dawson LA. in, DeVita, Lawrence and Rosenberg, eds. Cancer: Principles and Practice of Oncology. Lippincott Williams and Wilkins. 9th edition. 2011. Philadelphia, pp. 997-1018.

131. Hepatic tumors. **Di Bisceglie AM**, in Friedman and Keeffe, eds. Handbook of Liver Disease, third edition. Elsevier, Philadelphia, 2011. pp. 352-362.
132. Benign tumors, nodules and cystic diseases of the liver. **Di Bisceglie AM**, Befeler AS, in Schiff ER, Maddrey WC, Sorrell MF, eds. Schiff's diseases of the liver, 11th edition. Wiley-Blackwell. 2012. pp. 937-976.
133. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-943. as a clinical practice Guideline Member.
134. The history of the department of Internal Medicine at Saint Louis University. **Di Bisceglie AM**, Manning C, Holyoke A. Missouri Medicine 2012;109:115-119.
135. Diagnosis and management of patients with α 1-antitrypsin (A1AT) deficiency. Nelson DR, Teckman J, **Di Bisceglie AM**, Brenner DA. Clin Gastro Hepatol 2012;10:575-580.
136. Hepatic tumors. **Di Bisceglie AM**, in, Friedman LS and Keeffe EB, eds. Handbook of Liver Disease, third edition. Elsevier Saunders. Philadelphia, 2012. pp. 352-362.

LETTERS OF SCIENTIFIC INTEREST, OTHER MISCELLANEOUS PUBLICATIONS:

1. Terminology of sclerosing cholangitis. **Di Bisceglie AM**, Segal I. J Clin Gastroenterol 1982;4:480.
2. Plasmodium falciparum malaria in the Southern Transvaal. **Di Bisceglie AM**. S Afr Med J 1985;67:529.
3. (Comment) Transgenic mouse model for the chronic hepatitis B surface antigen carrier state. **Di Bisceglie AM** and Hoofnagle JH. Hepatology 1986;6:532-533.
4. Recombinant α -interferon: a promissory note in non-A, non-B chronic hepatitis. Hoofnagle JH, **Di Bisceglie AM**. Gastroenterology 1987;93:658-659.
5. (Tape) Treatment of chronic viral hepatitis. **Di Bisceglie AM**. Practical Reviews in Gastroenterology 1989;3.
6. Antibody to hepatitis C virus in patients with chronic non-A, non-B hepatitis and other chronic liver diseases. **Di Bisceglie AM**. Liver Update 1990;4:3-4.
7. Factors predicting the outcome of alpha interferon therapy for chronic non-A, non-B (type C) hepatitis. **Di Bisceglie AM**. Liver Update 1990;4:5-6.
8. Development of cirrhosis following chronic non-A, non-B hepatitis. **Di Bisceglie AM**. Liver Update 1988;2:3-4.

9. (Book Review) Neoplasms of the liver. **Di Bisceglie AM.** Hepatology 1988;8:1178-79.
10. (Comment) Treatment of hepatocellular carcinoma. **Di Bisceglie AM.** Hepatology 1991;13:802-803.
11. Hepatocellular carcinoma: Recent developments. **Di Bisceglie AM.** Prac Rev Gastro 1991; 5: No 8.
12. Early diagnosis of hepatocellular carcinoma in Italy. Dioguardi N, Barbara L, Bolondi L, Colombo M, **Di Bisceglie AM,** Dusheiko G, Gozzetti G, Ohto M, Okuda K, Verme G. J Hepatology 1992;14:401-403.
13. (Book review) The hepatitis delta virus. **Di Bisceglie AM.** Gastroenterology 1993;105:1586-1588.
14. Correspondence (reply): Aspartate aminotransferase and iron status - lack of support for covariation. Bacon BR and **Di Bisceglie AM.** Gastroenterology 1993;104:665.
15. (Book review) Histopathology of the liver. **Di Bisceglie AM,** Hoofnagle JH. Gastroenterology 1994;107:598-599.
16. Combined infection with hepatitis B and hepatitis C. **Di Bisceglie AM.** Hepatitis forum. Abbott Labs 1994;p.12.
17. (Tape) Hepatitis C recommendations. **Di Bisceglie AM.** Audio Journal of Haematology. 1994;2 No 1.
18. (Images in Medicine) A patient with cryoglobulinemia and hepatitis C. Shakil AO, **Di Bisceglie AM.** N Engl J Med 1994;331:1624.
19. (Letter) Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome. Marrone A, **Di Bisceglie AM,** Fox P. J. Hepatol 1995;22:599.
20. Foreword for Viral Hepatitis Reviews. **Di Bisceglie AM.** Viral Hepatitis Reviews 1995;1:1.
21. Is there a role for hepatitis B vaccine in cirrhosis? **Di Bisceglie AM,** Consultant. June 1995;762.
22. A link between chronic hepatitis B and recurrent cellulitis? **Di Bisceglie AM,** Consultant June 1996;1110.
23. (Highlights from the Int'l Congress of Internal Medicine Manila, 1996) Seroprevalence of hepatitis B and C: Asians vs. Caucasians. **Di Bisceglie AM.** Excerpta Medica 1996;1-4.

24. (Letter) Ribavirin for chronic hepatitis C. **Di Bisceglie AM**, Hoofnagle JH. *Ann Intern Med* 1996; 125:699.
25. Hepatocellular carcinoma. **Di Bisceglie AM**. The clinician's companion: expert perspectives on contemporary clinical issues in hepatitis C. 1997;39-40.
26. Emerging therapies for chronic hepatitis C. Audiotape: Beyond Monotherapy: Next Generation Therapies for Chronic Hepatitis C. **Di Bisceglie AM**. Education Initiative in Gastroenterology Meeting, New Orleans, May 17, 1998.
27. What next when a patient with hepatitis C refuses biopsy? (Editorial) **Di Bisceglie AM**. *Consultant* 1999;39:614.
28. Is therapy warranted in an older patient with hepatitis C? (Editorial) **Di Bisceglie AM**. *Consultant* 1999;39:1639.
29. The Clinician's Companion III: Expert perspectives on contemporary clinical issues in hepatitis C. CD-ROM. **Di Bisceglie AM**. Education Initiatives in Gastroenterology Meeting, June 18-19, 1999.
30. Rising Incidence of Hepatocellular Carcinoma. **Di Bisceglie AM**. *Medscape AASLD - Advances in Hepatocellular Carcinoma* December 1999. Available at: <http://gastroenterology.medscape.com/Medscape/CNO/1999/AASLD/public/index-AASLD.html>.
31. "Viral Hepatitis." **Di Bisceglie AM**. In, *Digestive Diseases Self-Education Program II (DDSEP)* for the American Gastroenterological Association, 2000.
32. "How do you manage the patient with hepatitis B and hepatitis C dual infection?" **Di Bisceglie AM**. *Medscape "Ask the Experts-Hepatitis C,"* December 14, 2000. Available at: <http://www.medscape.com/medscape/features/ResourceCenter/HepC/AskExperts/2000/12/HepC-ae08.html>.
33. "Raising hepatitis C awareness." **Di Bisceglie AM**. *HealthTalk Interactive's Hepatitis C Education Network*, January 30, 2001. Available at <http://www.healthtalk.com>.
34. The Clinician's Companion IV: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. Part 3: Insights into pathogenesis, treatment effects, and management of advanced liver disease. "Management of HCV-related cirrhosis and hepatocellular carcinoma." *Projects in Knowledge*, 2001, pp. 9-12. **Di Bisceglie AM**, Kwo PY, Rustgi VK.
35. (Consultations and Comments) Monoclonal gammopathy associated with hepatitis C – or something else? **Di Bisceglie AM**. *Consultant* 2001;41:650.

36. Letter to the Editor regarding "Hepatitis C Virus Infection" by Lauer and Walker. Bacon BR and **Di Bisceglie AM**. N Engl J Med, 2001;345:1425-1426.
37. **Di Bisceglie AM**, Rakela J. Hepatocellular carcinoma. In, The Clinician's Companion V: Expert perspectives on contemporary issues in hepatitis C. Part 2: Insights into the pathogenesis, treatment effects and management of advanced liver disease. Projects in Knowledge 2001. pp. 11-15.
38. Nonalcoholic liver disease: An emerging view of its significance and management. **Di Bisceglie AM**. Medscape Gastroenterology/DDW 2002 Conference Coverage. Available at <http://www.medscape.com/viewprogram/1846>.
39. Hepatitis C Virus (book review). **Di Bisceglie AM**. Gastroenterology 2000;116:224-225.
40. Natural history of hepatitis C. **Di Bisceglie AM**. In, Clinical Care Options for Hepatitis. Annual Update 2003. IMedOptions. pp. 3-12.
41. Malignant Liver Tumors: Current and Emerging Therapies (book review). **Di Bisceglie AM**. New Engl J Med 2004;350:202-203.
42. <http://www.medscape.com/viewprogram/3103>. **Di Bisceglie AM**. DDW 2004 CME Program.
43. Hepatocellular carcinoma. **Di Bisceglie AM**. In, Clinical Care Options for Hepatitis. Annual Update 2004. IMedOptions. pp. 149-158.
44. A common staging system for hepatocellular carcinoma. **Di Bisceglie AM**, Strasberg S. Hepatology 2004;39:550-551.
45. Distribution of hepatitis B virus (HBV) genotypes among patients with acute viral hepatitis. Lyra AC, Pinho JRR, Mello IMVGC, Malta F deM, Gomes MMS, **Di Bisceglie AM**, Lyra LGC, Carrilho FJ, da Silva LC. J Clin Gastroenterol 2005;39:81-81 (letter).
46. The Clinician's Companion VII: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. **Di Bisceglie AM**. "Relationship between chronic HCV infection and hepatocellular carcinoma." Projects in Knowledge, 2005, pp. 53-57. .
47. (Book review) Hepatocellular cancer: Diagnosis and treatment. **Di Bisceglie AM**. Gastroenterology 2005;129:393-394.
48. Does bare-stent TIPS increase the risk of hepatocellular carcinoma in patients with cirrhosis? **Di Bisceglie AM**. Nature Clinical Practice: Gastroenterology and Hepatology 2005;2:3 (Commentary).

49. The AASLD and Public Policy: Coming in out of the cold. **Di Bisceglie AM**. Hepatology 2007;45:1335-1336.
50. Pegylated interferon in the treatment of chronic hepatitis C virus infection – I and II. **Di Bisceglie AM**. UpToDate. Waltham, Ma. www.uptodate.com.
51. (Book review). Curbside consultation of Hepatology; 49 Clinical Questions. **Di Bisceglie AM**. Gastroenterology 2009 (in press).
52. (Letter) Prolonged therapy for hepatitis C with low-dose peginterferon. **Di Bisceglie AM**, Wright E, Dienstag JL. N Engl J Med 2009;360:1152-1153.
53. Management of posttransplant hepatitis C recurrence. **Di Bisceglie AM**. Gastroenterology & Hepatology 2009;5:692-3.
54. Audio CD. Management of chronic hepatitis C in the era of direct-acting antiviral agents. **Di Bisceglie AM**. Audio Diest Gastroenterology 2012;Vol 26 (Issue 17, September 7th).

ABSTRACTS

1. Why does alcohol affect the liver and pancreas differentially? **Di Bisceglie AM**, Segal I, Rabson AR, Diamond TH. Presented at annual meeting of South African Gastroenterology Society (SAGES) at Sun City, 1982.
2. Obstructive jaundice in South African Blacks. **Di Bisceglie AM**, Segal I, Oettle GJ, Hodkinson HJ. SAGES meeting, Cape Town, 1983.
3. Detection of markers of hepatitis B virus infection in urine of chronic carriers. **Di Bisceglie AM**, Dusheiko GM, Kew MC. S Afr Med J, 1984.
4. Liver histopathology in biliary obstruction due to chronic pancreatitis. **Di Bisceglie AM**, Paterson AC and Segal I. S Afr Med J, 1984.
5. Hepatitis B replication in adult carriers in an endemic area. Dusheiko GM, Bowyer S, Santos AP, Wolf P, **Di Bisceglie AM**, Song E, Kew MC. Hepatology 1983;3:809.
6. Detection of alphafoetoprotein messenger RNA in human hepatocellular carcinoma tissue. **Di Bisceglie AM**, Dusheiko GM, Ritchie M, Lee C-S, Beasley RP, Shouval D, Kew MC. Hepatology 1984;4:1042.
7. Prolonged recombinant leucocyte interferon (IFLA) treatment of chronic hepatitis. Dusheiko GM, **Di Bisceglie AM**, Bowyer S, Sacks E, Kew MC. 1984 International Symposium on Viral Hepatitis 1984; San Francisco.

8. Hepatitis B virus infection in urban black children in Soweto. **Di Bisceglie AM**, Dusheiko GM, Song E, Paterson AC Kew MC. *Hepatology* 1985;5:1046.
9. Obstructive jaundice in South African black and white populations: A retrospective study. Danilewitz M, Segal I, **Di Bisceglie AM**, Bank L. *S Afr Med J* 1985;68;521.
10. Changes in liver hepatitis B virus DNA associated with sero conversion from hepatitis B e antigen to antibody in chronic hepatitis B. **Di Bisceglie AM**, Hoofnagle JH. *Gastroenterology* 1986;90:1721.
11. Localization of the p-450 system in liver by in-situ hybridization. Rustgi VK, Jones DB, **Di Bisceglie AM**, Hoofnagle JH, Jones EA. *Hepatology* 1986;6:1220.
12. Detection of hepatitis B virus X gene protein in human hepatocellular carcinoma tissue by western blot. **Di Bisceglie AM**, Feinstone SF, Sninsky J, Kew MC, Dusheiko GM, Hoofnagle JH. *Hepatology* 1986;6:1220.
13. Loss of hepatitis B surface antigen from serum of chronic carriers. **Di Bisceglie AM**, Waggoner JG, Hoofnagle JH. *Hepatology* 1986;6:1220.
14. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon. Hoofnagle JH, Mullen KD, Jones DB, Rustgi VK, **Di Bisceglie AM**, Peters MG, Waggoner JG, Park Y, Jones EA. *Hepatology* 1986;6:1220.
15. Randomized controlled trial of a four month course of recombinant human alpha interferon in patients with chronic type B hepatitis. **Di Bisceglie AM**, Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi VK, Avigan MI, Park Y, Waggoner J, Jones EA. 1986 ISIR Meeting on the Interferon System; Finland.
16. Effect of recombinant human gamma interferon therapy on immune function in patients with chronic type B hepatitis. Lisker-Melman M, Ambrus J, Witzel N, Fauci AS, Park Y, **Di Bisceglie AM**, Hoofnagle JH. 1987 Intl Symp Viral Hep Liv Dis.
17. Alpha interferon treatment of patients with decompensated chronic hepatitis B. Kassianides C, **Di Bisceglie AM**, Rustgi VK, Lisker-Melman M, Mullen KD, Jones DB, Peters M, Park Y, Waggoner JG, Hoofnagle JH. 1987 Intl Symp Viral Hep Liv Dis.
18. Interferon therapy of chronic viral hepatitis. Hoofnagle JH, **Di Bisceglie AM**. 1987 Intl Symp Viral Hep Liv Dis.
19. Inhibition of hepatitis B viral replication by recombinant human gamma interferon. **Di Bisceglie AM**, Rustgi VK, Kassianides C, Lisker-Melman M, Waggoner JG, Park Y, Murray L, Hoofnagle JH. 1987 Intl Symp Viral Hep Liv Dis.

20. Treatment of chronic type B hepatitis with recombinant human alpha and gamma interferon in combination: A dose-finding study. **Di Bisceglie AM**, Kassianides CK, Lisker-Melman M, Rustgi VK, Murray L, Park Y, Waggoner JG, Hoofnagle JH. *Hepatology* 1987;7:1116.
21. Changes in lymphocyte subsets and immune function assays during treatment with gamma interferon in patients with chronic type B hepatitis. Lisker-Melman M, Suou T, Ambrus J, Peters M, Paxton H, Park Y, **Di Bisceglie AM**, Hoofnagle JH. *Hepatology* 1987;7:1143.
22. Detection of HBV DNA in serum during therapy for chronic type B hepatitis using a novel highly sensitive assay. Berninger M, **Di Bisceglie AM**, Hoofnagle JH, Reyes A, Schuster D, Hartley J. *Hepatology* 1987;7:1151.
23. Development of cirrhosis following chronic non A, non B hepatitis. **Di Bisceglie AM**, Kassianides CK, Lisker-Melman M, Waggoner JG, Martin P, Murray L, Park Y, Hoofnagle JH. *Gastroenterology* 1988;94:A535.
24. Changes in immune function and lymphocyte subsets in patients with chronic non A, non B hepatitis treated with recombinant human alpha interferon. Lisker-Melman M, Suou T, Moreno-Otero R, **Di Bisceglie AM**, Murray L, Hoofnagle JH. *Gastroenterology* 1988;94:A564.
25. The role of hepatitis B virus infection in hepatocellular carcinoma in the United States. **Di Bisceglie AM**, Sjogren M, Klein J, Waggoner JG, Order S. *Falk Symposium on Liver Cell Cancer* 1988.
26. Absence of novel transforming DNA sequences in human hepatocellular carcinoma. **Di Bisceglie AM**, Dusheiko GM, Kew MC. *Falk Symposium on Liver cell Cancer* 1988.
27. Detection of delta virus RNA and antigen in serum of patients: utility in monitoring therapy of chronic delta hepatitis. **Di Bisceglie AM**, Bergmann, K, Negro F, Smedile A, Hoofnagle JH. 1988 Hepatitis B Viruses Meeting.
28. Elevation of bile acids in liver disease are more closely related to reductions in hepatic function than development of portasystemic shunts. Arns PA, **Di Bisceglie AM**, Waggoner JG, Hoofnagle JH, Wilkinson GR, Branch RA. *Hepatology* 1988;8:1277.
29. Successful treatment of hepatitis B virus-associated glomerulonephritis with recombinant human alpha inteferon. Lisker- Melman M, Webb D, **Di Bisceglie AM**, Kassianides C, Martin P, Rustgi VK, Waggoner JG, Park Y, Murray L, Hoofnagle JH. *Hepatology* 1988;8:1269.
30. A randomized, double blind, placebo-controlled trial of alpha interferon therapy for chronic non A, non B hepatitis. **Di Bisceglie AM**, Kassianides C, Lisker-Melman M, Martin P, Murray L, Hoofnagle JH. *Hepatology* 1988; 8:1222.

31. Elevated serum alanine aminotransferase activities among sexual partners and household contacts of persons with non A, non B hepatitis. Everhart JE, **Di Bisceglie AM**, Alter H, Kassianides C, Martin P, Lisker-Melman M, Hoofnagle JH. *Hepatology* 1988;8:1270.
32. Non A, Non B hepatitis leads to rapidly progressive liver disease in patients with human immunodeficiency virus infection. Martin P, **Di Bisceglie AM**, Kassianides C, Lisker-Melman M, Hoofnagle JH. *Gastroenterology* 1989;96:A627.
33. Factors predicting the outcome of alpha interferon therapy for chronic non A, non B hepatitis. **Di Bisceglie AM**, Lisker-Melman M, Martin P, Kassianides C, Murray L, Hoofnagle JH. *Gastroenterology* 1989;96:A593.
34. Liver transplantation for hepatitis B viral infection. Lucey MR, Rosenthal S, Martin P, **Di Bisceglie AM**, Campbell D, Nostrant T, Appelman HD. *Gastroenterology* 1989;96:A624.
35. Intrahepatic markers of hepatitis delta virus infection: a study by in situ hybridization. Negro F, Bonino F, **Di Bisceglie AM**, Hoofnagle JH, Gerin JL. *J Hepatol* 1989;9:S196.
36. Assessment of HBV DNA in serum using the polymerase chain reaction: Clinical implications in chronic hepatitis B. Baker BL, **Di Bisceglie AM**, Miller RH, Kaneko S, Hoofnagle JH. *Hepatology* 1989;10:576.
37. Detection of antibody to hepatitis C virus in patients with various chronic liver diseases. **Di Bisceglie AM**, Alter H, Kuo G, Houghton M, Hoofnagle JH. *Hepatology* 1989;10:581.
38. Hepatic manifestations of chronic granulomatous disease of childhood. Korenman JC, Travis WD, Gallin JL, Melnick DA, **Di Bisceglie AM**. *Hepatology* 1989;10:655.
39. Blood-borne non-A, non-B hepatitis (PT-NANB): Immunohistochemical identification of disease and hepatitis C virus-associated antigen(s). Krawczynski K, Kuo G, **Di Bisceglie AM**, Houghton M, Bradley DW. *Hepatology* 1989;10:580.
40. Recurrence of hepatitis C after liver transplantation. Martin P, Munoz SJ, **Di Bisceglie AM**, Waggoner JG, Armenti V, Moritz M, Jarrell B, Maddrey WC. *Gastroenterology* 1990;98:A606.
41. Assessment of HBV DNA in serum using the polymerase chain reaction: Correlation with other serological and biochemical markers. Baker, **Di Bisceglie AM**, Waggoner JG, Miller RH, Kaneko S, Hoofnagle JH. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
42. Loss of hepatitis B surface antigen following treatment of chronic hepatitis B with alpha interferon. Korenman JC, **Di Bisceglie AM**, Baker BL, Waggoner JG, Hoofnagle JH. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.

43. The significance of concomitant chronic hepatitis B and hepatitis C virus infection. Fong TLF, **Di Bisceglie AM**, Waggoner JG, Hoofnagle JH. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
44. Detection of hepatitis C virus RNA by the polymerase chain reaction. Cristiano K, Baker B, **Di Bisceglie AM**, Feinstone SM. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
45. Blood-borne non A, non B hepatitis: Detection and identification of hepatitis C virus and disease associated antigen (HCAG) in hepatocytes. Krawczynski K, Kuo G, Houghton M, Alter M, **Di Bisceglie AM**, Bradley D. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
46. Clinical effectiveness in enzyme replacement in Gaucher's Disease. Barton NM, Brady RO, Doppelt SH, Mankin HJ, **Di Bisceglie AM**, Hill SC, Verederese CL, Graham OC, Argoff CE, Grewal RP, Yu K-T. Clin Res 1990.
47. Hepatitis C virus (HCV) in the blood and bone marrow of patients with aplastic anemia (AA). Frickhofen N, Mishler K, Rosenfeld S, Hibbs J, Anderson S, **Di Bisceglie AM**, Alter HJ, Weiner M, Feinstone SM, Young N. Blood 1990.
48. The contribution of HCV infection to liver disease in HBsAg carriers. Lok ASF, Ma DCK, Lai CL, **Di Bisceglie AM**, Chung HT. Presented at the 1990 meeting of the International Association for the Study of the Liver in Gold Coast, Australia.
49. Hepatocellular HCV-associated antigen and antibody: Viral specificity and relation to natural history of infection. Krawczynski K, Beach M, **Di Bisceglie AM**, Kim J, Alter M, Bradley D, Reyes G. Hepatology 1990;12:905.
50. Liver histopathologic changes following prolonged therapy of chronic delta hepatitis with recombinant alpha interferon. Kleiner DA, Axiotis CA, Lisker-Melman M, Martin P, Kassianides C, Bergasa NV, Korenman JC, Baker BL, Raffeld M, Hoofnagle JH, **Di Bisceglie AM**. Hepatology 1990;12:846.
51. Ten year follow up of post-transfusion non-A, non-B hepatitis: Histopathology and relationship to hepatitis C virus. **Di Bisceglie AM**, Goodman Z, Ishak KG, Hoofnagle JH, Melpolder J, Alter HJ. Hepatology 1990;12:845.
52. In chronic hepatitis B loss of serum hepatitis B viral DNA (HBV DNA) detectable by polymerase chain reaction (PCR) usually occurs at the time of loss of hepatitis B surface antigen (HBsAg). Korenman J, Baker B, Waggoner JG, **Di Bisceglie AM**, Hoofnagle JH. Hepatology 1990;12:845.

53. Long term treatment of duck hepatitis B virus (DHBV) infection with 2'3' dideoxyguanosine (ddG). Korenman JC, Martin P, Ford H, Nichols D, O'Brien M, Hoofnagle JH, Broder S, **Di Bisceglie AM**, Mitsuya H. *Hepatology* 1990;12:880.
54. Treatment of patients with decompensated cirrhosis due to chronic hepatitis B with recombinant human alpha interferon. Hoofnagle JH, **Di Bisceglie AM**, Baker, B, Korenman JC, Bergasa N, Fong TL, Waggoner JG, Park Y. *Hepatology* 1990;12:846.
55. High levels of serum HBV-DNA and HBsAg in acute hepatitis B virus infection predict progression to chronicity. Fong TL, **Di Bisceglie AM**, Waggoner JG, Biswas R, Hoofnagle JH. *Hepatology* 1990;12:845.
56. Prevalence of anti-HCV in patients with various liver diseases in Korea. Yoo JY, Shin HK, Park CK, Chung KW, Sun HS, Chung WK, **Di Bisceglie AM**, Waggoner JG, Hoofnagle JH. *Hepatology* 1990;12:975.
57. Ribavirin therapy for 6 months in patients with chronic hepatitis C. **Di Bisceglie AM**, Fong T-L, Fried MW, Swain MG, Bergasa NV, Shindo M, Hoofnagle JH. *Gastroenterology* 1991;100:A734.
58. Cytokine mRNA expression in the liver of patients with chronic hepatitis B. Shindo M, Mullin GE, **Di Bisceglie AM**, Fong T-L, Braun-Elwert L, Hoofnagle JH, Jones EA, James SP. *Gastroenterology* 1991;100:A734.
59. Clinical correlations of serum HCV RNA levels in patients with chronic hepatitis C. Shindo M, **Di Bisceglie AM**, Cheung L, Shih JW, Hoofnagle JH. *Gastroenterology* 1991;100:A795.
60. Changes in hepatitis C virus RNA in serum associated with alpha interferon therapy. Shindo M, **Di Bisceglie AM**, Cheung L, Shih J, Baker B, Feinstone SM, Cristiano K, Hoofnagle JH. *Hepatology* 1990;12:884.
61. A pilot study of 2'3'dideoxyinosine (DDI) in chronic hepatitis B. Fried MW, Korenman J, Hoofnagle JH, **Di Bisceglie AM**, Park Y, Waggoner JG, Mitsuya H, Yarchoan R, Broder S. *Gastroenterology* 1991;100:A741.
62. Expression of transforming growth factor alpha (TGFA) in human hepatocellular carcinoma (HCC). Hsia CC, Axiotis CA, **Di Bisceglie AM**, Tabor E. *Proc Am Soc Cancer Res* 1991;32:51.
63. A novel non-sense mutation in the pre-C region of hepatitis B virus (HBV) associated with clearance of hepatitis B e antigen and progressive liver disease. Lee J-H, Zeldis JB, Baker B, Waggoner JG, **Di Bisceglie AM**. *Hepatology* 1991;14:76A.

64. Persistent hepatic HBV-DNA after clearance of HBsAg from serum of patients with chronic hepatitis B. Fong T-L, **Di Bisceglie AM**, Feinstone SM, Waggoner JG, Axiotis CA, Hoofnagle JH. *Hepatology* 1991;14:130A
65. Hepatitis C virus (HCV) RNA in serum and liver during acute HCV infection in chimpanzees. Shindo M, Feinstone SM, **Di Bisceglie AM**. *Hepatology* 1991;14:118A.
66. The monoethylglycinexylidide (MEGX) test of hepatic function in chronic viral hepatitis. Fried MW, Fong T-L, Swain MG, Havorka R, Ruddel M, Barnett JA, Hoofnagle JH, **Di Bisceglie AM**, Fong EA. *Hepatology* 1991;14:271A.
67. Quantitation of hepatitis C virus RNA in serum using the polymerase chain reaction and a colorimetric enzymatic detection system. Shindo M, **Di Bisceglie AM**, Silver J, Limjoco T, Hoofnagle JH Feinstone SM. *Hepatology* 1991;14:64A.
68. Comparison of autoimmune (AI) and hepatitis C virus (HCV) related chronic hepatitis. Fried MW, Draguesku J, Shindo M, Simpson LH, Gracey D, Banks SM, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1991;14:61A.
69. Co-expression of transforming growth factor-alpha and hepatitis B surface antigen in the same hepatocytes of human liver tissue adjacent to hepatocellular carcinoma. Hsia CC, Axiotis CA, **Di Bisceglie AM**, Tabor E. *Hepatology* 1991;14:109A.
70. State of HBV genomes in cultured human and chimpanzee peripheral blood mononuclear cells following mitogen and cytokine treatment. Mueller C, **Di Bisceglie AM**, Gerin J, Korba B. *Hepadnaviruses meeting*. Paris,1991.
71. HBV DNA by polymerase chain reaction in serum of patients with chronic delta hepatitis. Simpson LH, Hoofnagle JH, **Di Bisceglie AM**. *Fourth International Symposium on Hepatitis Delta Virus and Liver Disease*. Rhodes, 1992.
72. Accurate quantitation of hepatitis B virus DNA in human serum with a new rapid chemiluminescent test: Hybrid capture HBV DNA assay. Garcia M, Lazar C, Impraim C, Challberg S, **Di Bisceglie AM**, Lorinez A. *5th International Forum on AIDS, Hepatitis and other blood-borne diseases*. Atlanta, 1992.
73. Development of hepatocellular carcinoma after prolonged hepatitis C viral infection. **Di Bisceglie AM**, Simpson LH, Lotze MT, Hoofnagle JH. *Hepatology* 1992;16:530.
74. HCV RNA in liver allografts: Correlation with histopathology. Fried MW, Thung SN, Shindo M, Thiese ND, Schwartz M, Borcich T, Miller C, **Di Bisceglie AM**. *Gastroenterology* 1992;102:A808.

75. Hepatitis B virus (HBV) suppression during long-term therapy with ribavirin. Fried MW, Fong T-L, Swain MG, Park Y, Simpson LH, Hoofnagle JH, **Di Bisceglie AM**. *Gastroenterology* 1992;102:A808.
76. Expression of mutant p53 in human HCC from two geographic areas. Hsia CC, Axiotis CA, **Di Bisceglie AM**, Kleiner D, Tabor E. *Proc Am Assoc Canc Res* 1992;33:108.
77. Hepatitis C viral antigen (HCVAg) in liver: Effect of antiviral therapy. **Di Bisceglie AM**, Krawczynski K, Brazzeal D, Hoofnagle JH. *Hepatology* 1992;16:131A.
78. Immunohistochemical staining for RB tumor suppressor gene product: Application to human HCC. Hsia CC, **Di Bisceglie AM**, Tabor E. *Hepatology* 1992;16:57A.
79. FIAU, a new oral antiviral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Fried MW, **Di Bisceglie AM**, Straus SE, Savarese B, Beames MP, Hoofnagle JH. *Hepatology* 1992;16:127A.
80. A capture assay for HCV RNA using a human monospecific antibody to core antigen of HCV. Shindo M, Akatsuka T, **Di Bisceglie AM**, Donets M, Scaglione L, Hoofnagle JH, Feinstone SM. *Hepatology* 1992;16:70A.
81. Hepatic histology in apparently healthy blood donors with hepatitis C viral infection confirmed by PCR. Adania RS, Silva AEB, **Di Bisceglie AM**, Bordin JO, Lanzoni VP, Ferraz MLG. *Hepatology* 1992;16:194A.
82. HBV DNA by PCR in individuals with anti-HBc as the only marker of hepatitis B virus infection. Silva AEB, McMahan BJ, Parkinson AJ, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1992;16:65A.
83. The effect of FIAU on chronic HBV infection in HIV-infected subjects. Paar DP, Hooton TM, Smiles KA, **Di Bisceglie AM**, Havlir DV, Richman DD, Gretch DR, Corey L, Straus SE. *ICAAC*, 1992.
84. Immune mechanisms of liver damage in viral hepatitis. **Di Bisceglie AM**. *Arch Arg Enf Ap Dig* 1992;6:87-88.
85. Hepatocellular carcinoma - an update. **Di Bisceglie AM**. *Arch Arg Enf Ap Dig* 1992;6:88-89.
86. Presence of HBV in peripheral blood mononuclear cells from HCV infected patients without markers of HBV infection. Korba BE, Muller C, **Di Bisceglie AM**, Gerin JL. 1992, *Molecular Biology of Hepatitis B Viruses*, University of California - San Diego.

87. Prospects for new antiviral agents in the therapy of chronic delta hepatitis. **Di Bisceglie AM**. 1992, Fourth International Symposium on Hepatitis Delta Virus and Liver Disease, Greece.
88. The effect of cholesterol-lowering agents on tissue and plasma cholesterol in Niemann-Pick disease, type C. Patterson MC, Higgins JJ, Abel RB, Schiffmann R, Parker CC, Argoff C, Grewal RP, Yu K, **Di Bisceglie AM**, Pentchev PG, Brady RO, Barton NW. 1992, AAN Scientific Program.
89. Diagnosis of chronic hepatitis C: Comparison of immunoassays and the polymerase chain reaction. Silva AE, Hosein B, Wisneiwolski R, Fang C, Shindo M, Waggoner JG, **Di Bisceglie AM**. *Gastroenterology* 1993;104:A995.
90. Hepatitis C virus recurrence by polymerase chain reaction following orthotopic liver transplantation. Kiyasu P, **Di Bisceglie AM**, Lovell M, Stevenson W, Pruett T, Caldwell S, McCallum R. North American Conference of GI Fellows. Tampa, FL, Feb 1993.
91. Fulminant hepatic failure in patients undergoing liver transplantation: Evidence of a non-A, B, C,D,E syndrome. Ferraz MLG, Silva AEB, Campbell DA, **Di Bisceglie AM**, Lucey MR. *Gastroenterology* 1993;104:A901.
92. HCV RNA in sera of hemophiliacs with antibody to hepatitis C virus (HCV): Relationship to HIV infection and liver failure. Eyster ME, Silva AE, **Di Bisceglie AM**, Goedert JJ. IXth International Conference on AIDS. Berlin, 1993.
93. HCV RNA and cytokine mRNA in liver of patients with chronic hepatitis C: Effect of alpha interferon therapy. Shindo M, Hoofnagle JH, Feinstone SM, **Di Bisceglie AM**. 1993 International Symposium on Viral Hepatitis and Liver Disease, Tokyo.
94. Use of confirmatory tests for HCV infection in patients with hepatocellular carcinoma. Mangia A, Vallari D, **Di Bisceglie AM**. 1993 International Symposium on Viral Hepatitis and Liver Disease, Tokyo.
95. Hepatitis C virus recurrence after orthotopic liver transplantation: Clinical features during the 1st year. Kiyasu P, **Di Bisceglie AM**, Lovell M, Gaffey M, Lobo P, Ishitani M, Stevenson W, Pruett T, Caldwell S. *Gastroenterology* 1993;104:A928.
96. The physical state of the negative strand HCV RNA in serum. Shindo M, **Di Bisceglie AM**, Akatsuka T, Fong TL, Donets M, Scaglione L, Hoofnagle JH, Feinstone SM. 1993 International Symposium on Viral Hepatitis and Liver Disease, Japan.
97. Randomized, double blind placebo-controlled trial of ribavirin therapy for chronic hepatitis C. **Di Bisceglie AM**, Fried MW, Swain MG, Bergasa NV, Yurdaydin C, Simpson LH, Sallie R, Conjeevaram H, Kleiner D, Park Y, Hoofnagle JH. *Hepatology* 1993;18:93A.

98. Absence of hepatitis C viral (HCV) infection in Alaska patients with hepatocellular carcinoma (HCC) not related to hepatitis B. Chung Y-H, McMahon B, Lanier A, Parkinson AJ, Zanis C, **Di Bisceglie AM**. *Hepatology* 1993;18:82A.
99. Serum HBV DNA levels correlate with the presence of hepatic injury in patients with chronic hepatitis B seronegative for HBeAg. Mangia A, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1993;18:115A.
100. Long term follow up of hepatitis B virus (HBV) related glomerulonephritis treated with alpha interferon. Conjeevaram H, Balow JE, Austin H, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1993;18:146A.
101. Hepatitis delta virus (HDV) RNA in serum of patients with chronic delta hepatitis. Battegay M, Simpson L, Sallie R, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1993;18:223A.
102. Perinatal transmission of hepatitis C. DeVoid DE, Minkoff H, Goedert J, Biswas R, **Di Bisceglie AM**. *Hepatology* 1993;18:229A.
103. Ground glass hepatocytes in chronic hepatitis B: Quantitation and clinical significance. Conjeevaram HS, Kleiner DE, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1993;18:227A.
104. The 5' End of HCV: Characterization by end to end RNA ligation mediated polymerase chain reaction. Sallie R, Chia S-C, Hoofnagle J, **Di Bisceglie AM**, Feinstone SM. *Hepatology* 1993;18:78A.
105. Alpha-1-antitrypsin (AAT) levels and phenotypes and progression of liver disease in chronic viral hepatitis. Mahaney K, Brantly M, Redwine J, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1993;18:272A.
106. Genomic variability of the hepatitis C virus (HCV): Development of mutations during antiviral therapy. Mahaney K, **Di Bisceglie AM**, Hoofnagle JH, Sallie R. *Hepatology* 1993;18:92A.
107. Prevalence and significance of hepatitis C viral (HCV) infection among alcoholics without evidence of liver disease. Herion D, George DT, Eckardt MJ, Beames M, **Di Bisceglie AM**. *Hepatology* 1993;18:235A.
108. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon. Bacon BR, Rebholz AE, Fried M, **Di Bisceglie AM**. *Hepatology* 1993;18:150A.
109. Hepatic iron concentration as a predictor of response to alpha interferon therapy in chronic hepatitis C. Olynk J, Reddy R, **Di Bisceglie AM**, Jeffers LJ, Parker T, Radick J, Schiff ER, Bacon BR. *Hepatology* 1993;18:90A.

110. Distinctive histopathological features of chronic hepatitis B in children. Kleiner DE, Conjeevaram H, Hoofnagle JH, **Di Bisceglie AM**. *Hepatology* 1993;18:118A.
111. Nalmefene therapy is associated with the relief of the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Bergasa NV, Alling DW, Talbot TL, Chia SC, Souppaya M, Conjeevaram H, Sallie R, Yurdaydin C, Wells M, Swain MG, **Di Bisceglie AM**, Hoofnagle JH, Jones EA. *Hepatology* 1993;18:177A.
112. HBV DNA detection in anti-HBe positive HBsAg carriers: comparison of a non-isotopic hybridization assay and the polymerase chain reaction. Silva AE, Mangia A, Lopez EPA, Lanzoni VP, Ferraz ML, **Di Bisceglie AM**. *J Hepatology (for EASL)*, 1993.
113. Ligase chain reaction for detection of mutation in pre-core region of HBV genome. Mangia A, Mushawar IK, Berkenmeyer L, **Di Bisceglie AM**. *Hepatology* 1994;20:307A.
115. HLA-A2 restricted cytotoxic T cells (CTL) recognize hepatitis C virus encoded NS4 and NS5 peptides strongly binding to HLA-A2. Bategay M, Akatsuka T, **Di Bisceglie AM**, Fikes J, Wentworth P, Ching WM, Berzofsky JA, Hoofnagle JH, Feinstone SM. 2nd International Meeting on Hepatitis C and Related Viruses. California, 1994.
116. Hepatitis C viral (HCV) markers in serum and liver of chronically infected patients. **Di Bisceglie AM**, Chung Y-W, Dailey PJ, Shakil AO, Krawczynski K, Hoofnagle JH. *Hepatology* 1994;20:236A.
117. Correlation between hepatic and serologic markers of HBV infection in patients with chronic hepatitis B. **Di Bisceglie AM**, Kuhns MC, McNamara A, Hoofnagle JH. *Hepatology* 1994;20:296A.
118. Serum levels of IgM anti-HBc in patients with chronic hepatitis B. Changes with therapy. Hayashi PH, Beames MP, Hoofnagle JH, **Di Bisceglie AM**. *Gastroenterology* 1994;106:A905.
119. A novel and rapid method of genotyping hepatitis C virus. Mahaney K, Tedeschi V, **Di Bisceglie AM**, Maertens G, Sallie R. *Gastroenterology* 1994;106:A936.
120. Liver histopathology in blood donors with hepatitis C and normal serum ALT levels. Shakil AO, Conry-Cantilena C, Melpolder J, Alter HJ, Hoofnagle JH, Krawczynski K, Tedeschi V, **Di Bisceglie AM**. *Gastroenterology* 1994;106:A981.
121. Interaction between HBV, HDV, and HCV in hemophiliacs with HIV infection. Eyster ME, Sanders JC, **Di Bisceglie AM**. *Gastroenterology* 1994;106:A889.
122. Expression of transforming growth factor alpha (TGF) in liver of patients with chronic viral hepatitis. Chung YH, **Di Bisceglie AM**. *Gastroenterology* 1994;106:A877.

123. FIAU Toxicity: Progression lactic acidosis, hepatic failure and pancreatitis. Fried MW, Sallie R, Conjeevaram H, **Di Bisceglie AM**, Park Y, Savarese B, Straus SE, Hoofnagle JH. 34th ICAAC. Florida, 1994.
124. Genotypic analysis of hepatitis D isolates from patients with chronic delta hepatitis in the US: Disease severity and response to interferon. Shakil AO, Casey JL, Niro GA, **Di Bisceglie AM**, Hoofnagle JH, Gerin JL. *Hepatology* 1994;20:308A.
125. Transforming growth factor- (TGF-) in the liver before and after interferon- (IFN-) for chronic hepatitis B. Morimitsu Y, Kleiner, Jr DE, Hsia CC, **Di Bisceglie AM**, Tabor E. *Hepatology* 1994;20:299A.
126. Ground glass hepatocytes in chronic hepatitis B: Changes with alpha interferon therapy. Conjeevaram HS, Kleiner DE, Sallie R, Marrone A, **Di Bisceglie AM**, Hoofnagle JH. *Hepatology* 1994;20:299A.
127. Serum levels of hepatitis B e antigen (HBeAg) in patients with chronic hepatitis B: Changes with therapy. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, **Di Bisceglie AM**. *Gastroenterology* 1995;108:A1081.
128. Analysis of hepatitis delta virus RNA and viral genotypes in patients with chronic delta hepatitis in southern Europe. Shakil AO, Casey JL, Hoofnagle JH, **Di Bisceglie AM**, Gerin JL, Hadziyannis S. Fifth Int'l Symposium on Hepatitis Delta Virus and Liver Disease, 1995.
129. Sequence variability of hepatitis delta virus genome: analysis of global distribution of genotypes and subtypes. Shakil AO, Casey JL, Niro GA, Hadziyannis S, **Di Bisceglie AM**, Hoofnagle JH, Gerin JL. Fifth Int'l Symposium of Hepatitis Delta Virus and Liver Disease, 1995.
130. Long-term therapy with ribavirin for chronic hepatitis C. Hoofnagle JH, Conjeevaram HS, Kleiner DE, Lau DT, **Di Bisceglie AM**. Third Int'l Meeting on Hepatitis C Virus and Related Viruses, 1995.
131. Hepatic iron concentration (HIC) in end stage liver disease (ELSD) 2° to chronic hepatitis C (HCV) and/or alcoholic liver disease (ALD). Reddy KR, Bacon BR, Tzakis A, Neuschwander-Tetri BA, Jeffers LJ, **Di Bisceglie AM**, Bernstein DE, Weppler D, Webb M, Nery J, de Medina M, Vioianna A, Schiff ER. *Hepatology* 1995;22:275A.
132. Two year course of ribavirin for chronic hepatitis C. Hoofnagle JH, Conjeevaram HS, Kleiner DE, Lau D, **Di Bisceglie AM**. *Hepatology* 1995;22:118A.
133. Autologous lymphocyte therapy (ALT) for chronic hepatitis B: A preliminary study in chimpanzees. **Di Bisceglie AM**, Babbitt BP, Caplan B, Bhan AK, Rall CJN, Dienstag JL. *Hepatology* 1995;22:329A.

134. Hepatic expression of alpha-smooth muscle actin in chronic hepatitis C: Correlation with disease activity and changes with therapy. Poulos JE, Brunt EM, Janney CG, Bacon BR, **Di Bisceglie AM**. *Hepatology* 1995;22:278A.
135. Stimulation of c-JUN kinase by fibronectin and interleukin-1 alpha is associated with increased gene expression of stromelysin in lipocytes. Poulos JE, **Di Bisceglie AM**, Bellezzo JM, Weber JD, Britton RS, Bacon BR, Baldassare JJ. *Hepatology* 1995;22:293A.
136. Antigen independent activation of T cells obtained from chronic hepatitis B patients results in enhanced responses upon restimulation by HBV antigens. Hogan C, Caplan B, Bacon B, **Di Bisceglie AM**, Babbitt B. *Hepatology* 1995;22:264A.
137. Role of hepatitis G virus in cryptogenic liver disease. **Di Bisceglie AM**, Bacon BR, Neuschwander-Tetri BA, Yun A, Kim JP. *Gastroenterology* 1996;110:A1181.
138. Fibronectin and interleukin-1 stimulate ap-1-dependent gene expression in rat hepatic stellate cells. Poulos JE, Bellezzo JM, Weber JD, **Di Bisceglie AM**, Britton RS, Bacon BR, Baldassare JJ. *Hepatology* 1996;24:459A.
139. Liver transplantation in patients with chronic hepatitis C and alcoholism. Dhar SC, Solomon H, Bacon BR, **Di Bisceglie AM**. *Hepatology* 1996;24:502A.
140. Hepatic HCV RNA in alcoholic patients undergoing liver transplantation. Fan X, Neuschwander-Tetri BA, Poulos JE, Solomon H, **Di Bisceglie AM**. *Hepatology* 1996;24:508A.
141. Ribavirin therapy for chronic hepatitis C (CHC): A dose-duration dependent improvement in inflammatory activity. Kleiner DE, **Di Bisceglie AM**, Hoofnagle JH. U.S. and Canadian Academy of Pathology Meeting, 1997.
142. Hepatitis C-associated cryoglobulinemia presenting as necrotizing vasculitis of the gall bladder and appendix. Ramrakhiani S, Brunt EM, **Di Bisceglie AM**. American College of Gastroenterology, 62nd Annual Scientific Meeting, 1997.
143. Viral hepatitis in an elderly nursing home population. Chein NT, Horani M, Morley JE, **Di Bisceglie AM**. *JAGS* 1997;45:880.
144. Positron emission tomography (PET) scanning in the diagnosis of hepatocellular carcinoma. Combs CS, Lowe VJ, Wolverson MK, Brunt EM, Collins BT, Solomon H, **Di Bisceglie AM**. *Hepatology* 1997;26:242A.
145. Iron reduction therapy in chronic hepatitis C. **Di Bisceglie AM**, Bonkovsky H, Krawitt E, Grace N, Killenberg P, Hunt C, Chopra S, Reddy RK, Flamm S, Tavill AS, Ferguson R, Tamburro C, Osmack P, Bacon BR. *Hepatology* 1977;26:151A.

146. A comparison of hepatitis C viral quasispecies in liver and serum. Fan X, Neuschwander-Tetri BA, Poulos JE, Solomon H, **Di Bisceglie AM**. *Hepatology* 1997;26:300A.
147. Is hepatitis G virus hepatotropic?: Detection of HGV RNA in serum and liver tissue of patients undergoing liver transplantation. Fan X, Solomon H, Neuschwander-Tetri B, Poulos JE, **Di Bisceglie AM**. *Hepatology* 1997;26:92.
148. A proposal for grading and staging the histopathologic findings in nonalcoholic steatohepatitis (NASH). Brunt EM, Janney CG, **Di Bisceglie AM**, Neuschwander-Tetri BA, Bacon BR. *Mod Pathol* 1998;11:151A.
149. Comparison of 24 vs. 48 weeks of interferon and ribavirin in combination for patients with chronic hepatitis C not responding to previous therapy with interferon alone. **Di Bisceglie AM**, Rauscher, J, Smith-Wilkaitis N, Randall D, Koehler K, Bacon BR. US Rebetol Investigators' Meeting. Puerto Rico, 1998.
150. Expression of p-glycoprotein in human hepatocellular carcinoma and cirrhosis. Richart JM, Brunt EM, **Di Bisceglie AM**. AASLD Clinical Research Single Topic Conference, 1998.
151. Expression of C-MYC binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. Fan X, Xu Y, Shah D, Solomon H, Neuschwander-Tetri B, Ray RB, **Di Bisceglie AM**. AASLD Clinical Research Single Topic Conference, 1998.
152. Influence of hepatitis C virus genotype and development of hepatocellular carcinoma: A meta-analysis. Naeem M, **Di Bisceglie AM**. AASLD Clinical Research Single Topic Conference, 1998.
153. Effect of dietary iron loading in chimpanzees with chronic hepatitis C virus infection. **Di Bisceglie AM**, Bassett SE, Bacon BR, Lanford RE. *Gastroenterology* 1998;114:A1234.
154. Infection with hepatitis G (HGV) and hepatitis C (HCV) viruses in patients on chronic hemodialysis (HD). Bastani B, Frenchie D, Gellens M, **Di Bisceglie AM**. American Society of Nephrology 31st Annual Meeting, 1998.
155. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled phase II studies. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Carithers R, Rustgi V, **Di Bisceglie AM**, Balan V, Murray A, Rooney J, Jaffe HS for the Adefovir Dipivoxil HBV Study Team. *Hepatology* 1998;28:317A.
156. Prevalence of immunity to hepatitis A and B in patients undergoing orthotopic liver transplantation. Ramrakhiani S, Solomon H, Varma CR, Osmack P, Bacon BR, **Di Bisceglie AM**. *Hepatology* 1998;28:345A.

157. Interferon-ribavirin combination: sustained response in non-responders to interferon alone including patients with normal aminotransferases and predictors of poor response. Bacon BR, Rauscher JA, Smith-Wilkaitis NL, Randall DC, Koehler KM, Antal MJ, **Di Bisceglie AM**. *Hepatology* 1998;28:372A.
158. Iron grading: A proposal for a histologic system that includes the pattern, location and grade of stainable iron. Brunt EM, Britting RS, Olynyk JK, **Di Bisceglie AM**, Bacon BR. *Hepatology* 1998;28:423A.
159. Clinical improvement in patients with decompensated liver disease due to hepatitis B following treatment with lamivudine. Sponseller CA, Smith-Wilkaitis N, Bacon BR, **Di Bisceglie AM**. *Hepatology* 1998;28:589A.
160. Chronic hepatitis C viral infection in patients with normal serum aminotransferases. **Di Bisceglie AM**. Chronic hepatitis C viral infection in patients with normal serum aminotransferases. **Di Bisceglie AM**. *Hepatitis C: A Meeting Ground for the Generalist and the Specialist*, Washington DC, 1998.
161. The hepatitis C virus: Virology and future antiviral targets. **Di Bisceglie AM**. *Hepatitis C: A Meeting Ground for the Generalist and the Specialist*, Washington DC, 1998.
162. Inhibition of VSV/HCV pseudotype virus infectivity. Ray R, **Di Bisceglie AM**, Conley AJ, Fong SK, Hadlock KG, Meyer K. 6th International Symposium on Hepatitis C & Related Viruses. Bethesda, MD, 1999.
163. Neutralization of VSV/HCV pseudotype virus infectivity. Ray R, Meyer K, **Di Bisceglie AM**. 18th Annual Meeting American Society for Virology. University of Massachusetts, 1999.
164. Different ratio of nonsynonymous to synonymous nucleotide substitutions (d/ds) between serum and liver-derived HCV quasispecies. Fan X, Chambers TJ, **Di Bisceglie AM**. 6th International Symposium on Hepatitis C & Related Viruses. Bethesda, Maryland, 1999.
165. Changes in serum lipoprotein profile with interferon therapy in chronic hepatitis C. Naeem M, Bacon BR, Britton RS, **Di Bisceglie AM**. *Gastroenterology* 1999;116:A1203.
166. Identification of liver-specific quasispecies variants of hepatitis C virus (HCV) in chronically infected patients. Fan X, Solomon H, Ramrakhiani S, **Di Bisceglie AM**. *Gastroenterology* 1999;116:A1203.
167. Semi-quantitative detection of mRNA of C-MYC and C-MYC binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. Fan X, Xu Y, Shah D, Solomon H, Ramrakhiani S, Ray RB, **Di Bisceglie AM**. *Gastroenterology* 1999;116:A1203.

168. Can steatohepatitis (SH) coexist with other forms of chronic liver disease (CLD)? Brunt EM, Neuschwander-Tetri BA, **Di Bisceglie AM**, Janney CG, Bacon BR. US and Canadian Academy of Pathology, 1999.
169. Changes in reactivity over time to hepatitis C viral peptides from the hypervariable (HVRI) region. **Di Bisceglie AM**, Fan X. *Hepatology* 1999;30:361A.
170. Silent hepatitis B virus in HBsAg-seronegative hepatocellular carcinoma patients. Hsia C-C, Scudamore CH, **Di Bisceglie AM**, Momosaki S, Tabor E. *Hepatology* 1999;30:441A.
171. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Kew MC, Klein AS, Abrams RA, Sitzmann JV, Jones L, Sharma S, Bacon BR, **Di Bisceglie AM**, Groopman JD. *Hepatology* 1999;30:279A.
172. Compartmentalization of hepatitis C virus quasispecies. **Di Bisceglie AM** and Fan X. *Antiviral Therapy* 1999;4(Suppl 4); Abstract 13.
173. Interaction of HCV E1 and E2 glycoproteins with cell surface for pseudotype virus infectivity. Ray R, Meyer K, Lagging LM, **Di Bisceglie AM**. 21st US-Japan Hepatitis Panel, San Antonio, Texas, January 2000.
174. Sustained virologic response to combination therapy with interferon plus ribavirin in patients with chronic HCV infection and normal serum aminotransferases. Sreenarasimhaiah V, Bacon BR, Rauscher J, **Di Bisceglie AM**. 10th International Symposium on Viral Hepatitis and Liver Disease: *Antiviral Therapy* 2000;5(suppl 1), C96.
175. Genetic characterization of hypervariable regions of hepatitis C virus genotype 2. Fan X and **Di Bisceglie AM**. 10th International Symposium on Viral Hepatitis and Liver Disease: *Antiviral Therapy* 2000;5(suppl 1), C121.
176. Adaptive evolution of the hypervariable region 1 of the hepatitis C virus (HCV) genome in a liver transplant recipient. Fan X and **Di Bisceglie AM**. 10th International Symposium on Viral Hepatitis and Liver Disease: *Antiviral Therapy* 2000;5(suppl 1), C122.
177. The coexistence of steatohepatitis with other forms of chronic liver disease in liver biopsies. Brunt EM, Cordes BG, Neuschwander-Tetri BA, **Di Bisceglie AM**, Janney CG, Bacon BR. Falk Symposium 2000.
178. Hepatitis C and hepatocellular carcinoma in African Americans. **Di Bisceglie AM**, Schwartz M, Reddy R, Martin P, Gores GJ, Hussein K, Gish RG, Van Thiel DH, Younossi ZM, Tong MJ, Hassanein TI, Balart L, Fleckenstein JF. *Gastroenterology* 2000;118(2):A6514.
179. Design of the HALT-C trial (hepatitis C antiviral long-term treatment to prevent cirrhosis). **Di Bisceglie AM**, Bonkovsky HL, Dienstag JL, Everson GT, Lindsay KL, Gretch DR, Hoefs

JC, Lee WC, Lok AS, Tralka TS, Shiffman ML, Wright EC. *Gastroenterology* 2000;118(2):A6515.

180. A randomized, open label, multicenter, efficacy and safety study of new combinations of antiviral therapy in chronic hepatitis C: A preliminary report. **Di Bisceglie AM**, Bernstein D, Rustgi V, Gitlin N, Jeffers L, Simon D, Pappas SC, Campagna J. *Hepatology* 2000; (AASLD 2000 meeting).
181. Hepatitis C associated with cryoglobulinemia, glomerulonephritis and retinopathy. Ramrakhiani S, Salinas-Madrigal C, **Di Bisceglie AM**. Regional ACP Meeting 2000.
182. Rapidly progressive hepatitis C transmitted from an HCV-positive bone marrow donor. Tan D, Pincus S, **Di Bisceglie AM**. Regional ACP Meeting 2000.
183. Evolution of hepatitis C virus quasispecies after liver transplantation. Lyra AC, Fan X, Ramrakhiani S, **Di Bisceglie AM**. Digestive Disease Week, Atlanta, GA, May 2001.
184. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multi-center, prospective, randomized, controlled trial. Bacon BR, Bonkovsky HL, Banner B, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, **Di Bisceglie AM**. 4th Schering Hepatitis Investigators Week, Feb. 2000.
185. Hepatitis C virus genotype 4 infection in the United States: Clinical features and response to therapy. Ramrakhiani S, Bacon BR, Varma SC, Ramrakhiani S, **Di Bisceglie AM**. Digestive Disease Week, Atlanta, GA, May 2001.
186. Tan D, Fan X, Richart JM, Pincus SM, **Di Bisceglie AM**. Digestive Disease Week, Atlanta, GA, May 2001.
187. Competition and selection among different HCV strains. Fan X, Detre KM, Belle SH, Wei YL, Wiesner RH, Charlton MR, Schafer D, Zetterman RK, Lake JR, Hoofnagle JH, Everhart JE, **Di Bisceglie AM**. Digestive Disease Week, Atlanta, GA, May 2001.
188. Concurrence of steatohepatitis with chronic hepatitis C and other chronic liver diseases. Ramrakhiani S, Cordes B, Brunt EM, **Di Bisceglie AM**. Digestive Disease Week, Atlanta, GA, May 2001.
189. PEGylated (40 kda) interferon alfa-2a (PEGASYS) in new combination therapies: A report of a randomized, multicenter efficacy and safety study. **Di Bisceglie AM**, Bernstein DE, Rustgi VR, Gitlin N, Jeffers LJ, Dimon D, Campagna J, Pappas SC. *J Hepatology* 2001;34:143.

190. Ethnic differences in patients with primary biliary cirrhosis in the USA. Peters MG, **Di Bisceglie AM**, Flye N, Carithers R, Combes B, and The PUMPS Study Group. *Hepatology* 2001;(AASLD meeting 2001).
191. Genetic origin of unique hepatitis C viral (HCV) HVR1 variants after liver transplantation. Fan X, **Di Bisceglie AM**, Lyra AC, Xu Y. *Hepatology* 2001;34:416A.
192. Determination of *HFE* mutations in the paraffin-embedded liver biopsy blocks of patients with hepatocellular carcinoma. Younossi ZM, Steedman S, **Di Bisceglie A**, Gramlich T, Osmack P, Younoszai A, Grosso L, Cooper J, Duncan D, Seneca R. *Hepatology* 2001;34:504A.
193. Lack of deterioration of bone density in primary biliary cirrhosis with active therapy despite worsening liver disease. **Di Bisceglie AM**, Peters M, Loyet M. *Hepatology* 2001;34:526A.
194. Genetic diversity of the CD81 binding regions of HCV before and after liver transplantation. Lyra AC, Fan X, **Di Bisceglie AM**. *Hepatology* 2001;34:562A.
195. Long-term durability of sustained virologic response to antiviral therapy of hepatitis C. Bacon BR, **Di Bisceglie AM**, Thompson JA, Koehler KM. *Hepatology* 2001;34:606A.
196. Lifetime alcohol and drug abuse disorders are significantly more common in HALT-C patients compared to population controls while mood disorders are less common. Fontana RJ, Kronfol Z, Wright E, Lindsay K, Seeff L, Shiffman M, **Di Bisceglie A**, Bonkovsky H, Everson G, Lok ASF, Lee WM, Dienstag J, Morgan T, Morshima C, Ghany M for the HALT-C Study Group. *Gastroenterology* 2002 (DDW 2002).
197. HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2a in HCV non-responders: A 12-week kinetic study. Iftikar R, **Di Bisceglie A**, Pockros PJ, Rustgi VK, Schulman M, Martins EB. *Hepatology* 2002;36:360A.
198. Clonal nature of hepatitis C virus: Full length sequencing shows lack of recombination of HCV isolates from heterologous HCV positive recipient/donor pairs in liver transplantation. Fan X, Xu Y, Lang D, Detre KM, Belle SH, Wei YL, Wiesner RH, Charlton MR, Schafer D, Bass N, Roberts J, Korber BTM, Everhart JE, **Di Bisceglie AM**. *Hepatology* 2002;36:547A.
199. Derivation, origin-dating and assembly of ancestral hepatitis C virus (HCV) envelope sequences. Fan X, **Di Bisceglie AM**. *Hepatology* 2002;36:203A.
200. Retreatment of HCV non-responders with peginterferon and ribavirin: Results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Shiffman M and the HALT-C trial investigators. *Hepatology* 2002;36:295A.
201. Chemoprevention of hepatocellular carcinoma by Tamoxifen. **Di Bisceglie AM**, Osmack P, Brunt EM. *Hepatology* 2002;36:697A.

202. HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2A in HCV non-responders: A 12-week kinetic study. Iftikhar R, **Di Bisceglie AM**, Pockros PJ, Rustgi VK, Schulamn M, Martins EB. *Hepatology* 2002;36:360A.
203. Peripheral blood B cell expansion in HCV infection is not associated with activation or differentiation. Dustin LB, Ni J, Hembrador EG, Chambers TJ, **Di Bisceglie AM**, Dorante G, Talal AH, Jacobson IM, Rice CM. 9th International Meeting on HCV and Related Viruses, Center for the Study of Hepatitis C, Rockefeller University, 2002.
204. HCV quasispecies dynamics during combination therapy of peginterferon alfa 2A and ribavirin. Fan X, Droll DA, Xu Y, Chambers TJ, **Di Bisceglie AM**. *Gastroenterology* 2003;124:A776.
205. Gastrointestinal surgery in patients with cirrhosis. Hoffman MG, Longo WE, Bahadursingh A, **Di Bisceglie AM**. *Gastroenterology* 2003 (DDW 2003).
206. The presence of severe steatosis or steatohepatitis impairs response to antiviral therapy in patients with chronic hepatitis C. Harrison SA, Brunt EM, Oliver DA, Neuschwander-Tetri BA, **Di Bisceglie AM**, Bacon BR. *Hepatology* 2003;38:626A.
207. Monitoring HCV core antigen during antiviral therapy. **Di Bisceglie AM**, Strinko J, Osmack P. *Hepatology* 2003;38:430A.
208. Early pharmacokinetics, pharmacodynamics and hepatitis C viral kinetics on treatment with pegylated interferon (IFN) alfa-2a with or without ribavirin: characterization of the null responder. **Di Bisceglie AM**, Osmack P, Hoffman J, Strinko J. *Hepatology* 2003;38:316A.
209. Serum alpha-fetoprotein (AFP) levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: results from the HALT-C trial. **Di Bisceglie AM**, Dienstag J, Bonkovsky H, Sterling R, Chung R, Everhart J, Wright E, for the HALT-C investigators. *Hepatology* 2003;38:434A.
210. Image-guided liver biopsy in the evaluation of clinically suspected HCC: Correlation of fine needle aspiration (FNA) and core biopsy (BX). Ezenekwe AM, Brunt EM, Bialecki ES, Ponder TB, Collins BT, Bieneman BK, **Di Bisceglie AM**. Submitted to United States and Canadian Academy of Pathology Annual Meeting (2003).
211. The presence and spectrum of varices in the absence of cirrhosis in patients with chronic hepatitis C. Sanyal AJ, Fontana R, Everhart J, **Di Bisceglie AM**, Wright E. *Hepatology* 2003;38:218A.
212. HCV-specific immune responses at baseline do not predict virologic response to antiviral therapy in advanced hepatitis C. Morishima C, Ray R, Polyak SJ, Sullivan DG, Chang M, **Di**

- Bisceglie AM**, Lee WM, Bonkovsky HL, Gretch DR, Wright EC, Rothman AL, Koziel MJ, Lindsay KL. *Hepatology* 2003;38:263A.
213. Diabetic hepatosclerosis: perisinusoidal hepatic fibrosis without steatohepatitis among diabetics. Harrison SA, Brunt EM, Goodman ZD, **Di Bisceglie AM**. *Hepatology* 2003;38:266A.
214. Portal hypertensive gastropathy is prevalent amongst chronic hepatitis C non-responders with bridging fibrosis and early cirrhosis: results from the HALT-C trial. Fontana RJ, Sanyal AJ, Wright E, **Di Bisceglie AM**. *Hepatology* 2003;38:294A.
215. Host immune responses do not correlate with histologic injury: baseline analysis of the HALT-C trial in advanced hepatitis C disease. Rothman AL, Morishima C, Ray R, Bonkovsky HL, **Di Bisceglie AM**, Lee WM, Lindsay, KL, Gretch DR, Polyak SJ, Wright EC, Koziel MJ. *Hepatology* 2003;38:467A.
216. GP73, a resident Golgi membrane protein, appears in sera or patients with viral liver disease and hepatocellular cancer. Romano PR, Nikolaeva OV, Steel L, Fimmel CJ, Marrero J, Evans AA, Communale MA, Lok A, London WT, **Di Bisceglie AM**, Block TM. *Hepatology* 2003;38:768A.
217. Full length genome analysis of hepatitis C virus in patients with differential responses after combined therapy of pegylated interferon-alpha and ribavirin. Tan D, Yao E, Fan X, Chambers T, Tavis J, **Di Bisceglie AM**. *Gastroenterology* 2004;126:A686.
218. Antioxidant treatment does not substantially ameliorate the fall in hemoglobin in HCV patients treated with pegylated interferon alfa-2b and ribavirin. Bacon BR, Freilich BL, Siegner JM, O'Neill R, Kissinger J, Hoffmann JA, Britton RS, **Di Bisceglie AM**, Brass CA. *Gastroenterology* 2004;126:A233.
219. Genetic and biochemical evidence for action of ribavirin through the HCV RNA polymerase in vivo. Cannon NA, Metzger LM, Donlin MJ, Lyra A, Yao E, **Di Bisceglie AM**, Tavis JE. 11th International Symposium on hepatitis C and related viruses. Heidelberg, Germany. October 2004.
220. Full length sequencing of HCV identifies novel regions of the viral genome associated with response to antiviral therapy. **Di Bisceglie AM**, Tan D, Fan X, Tavis JE, Kuiken C. 11th International Symposium on Hepatitis C and Related Viruses. Heidelberg, Germany. October 2004.
221. Development of a replicon-based shuttle vector system for phenotypic characterization of HCV patient NS5B genes towards polymerase inhibitors. Middleton T, Lim HB, Pilot-Matias T, Tripathi R, Roth A, Koev G, Ng T, Liangjun L, Pithawalla R, Chen-C-M, Kati W, Mo H, **Di Bisceglie A**, Molla A. 11th International Symposium on Hepatitis C and Related Viruses. Heidelberg, Germany. October 2004.

222. Interferon-gamma stimulated chemokines predict treatment outcome in patients with chronic HCV infection. Butera D, Marukian S, Jacobson IM, **Di Bisceglie AM**, Chambers TJ, Rice CM, Dustin LB. 11th International Symposium on Hepatitis C and Related Viruses. Heidelberg, Germany. October 2004.
223. The epidemiology and survival of patients with hepatocellular carcinoma in the United States – A preliminary report from the Liver Cancer Network. Befeler AS, Marrero JA, Chari RS, Roberts L, Afdhal N, Van Thiel D, **Di Bisceglie AM**. *Hepatology* 2004;40(Suppl 1):216A.
224. Liver biopsy evaluation in work up of hepatic lesions suspicious for hepatocellular carcinoma. Bialecki A, Ezenekwe A, Brunt EM, Collins BT, Ponder TB, Bieneman BK, **Di Bisceglie AM**. *Hepatology* 2004;40(Suppl 1):312A.
225. Prevalence of insulin resistance (IR) and impact on treatment in chronic hepatitis C (CHC). Lok AS, Everhart JE, Chung RT, Padmanbhan L, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, **Di Bisceglie AM**, Le WM, Morgan TR, Ghany MG, Morishima C. *Hepatology* 2004;40(Suppl 1):314A.
226. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2A or alfa-2B with ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C. **Di Bisceglie AM**, Rustgi VK, Thuluvath P, Davis M, Ghalib R, Lyons MF, Ondovik MS, Lopez-Talavera JC, Hamzeh F. *Hepatology* 2004;40(Suppl 1):734A.
227. The natural history of chronic hepatitis B infection: a new computer simulation model to incorporate events subsequent to HBeAg seroconversion. Kim, WR, Veenstra D, Oloeje UH, Tafesse E, Atillasoy E, **Di Bisceglie AM**, Kowdley K. *Gastroenterology* 2005;128:A692.
228. Are serial liver biopsies useful in assessing disease progression in individuals with primary biliary cirrhosis? Saldana S, Frawley W, Combes B, Mills S, Markin R, Rubin R, Wheeler D, Contos M, West B, Flye N, Butsch R, Emerson S, Carithers R, Luketic V, Benner K, Peters M, **Di Bisceglie A**, McCashland T, Bass N, Lake J, Kowdley K, Boyer T, Martinez E, Munoz S, Boyer J, Garcia-Tsao G, Barnes D, Bonacini M, Donovan J, Rosoff L, May MJ. *Gastroenterology* 2005;128:A774.
229. Management of chronic hepatitis B – an analysis of physician practices. **Di Bisceglie A**, Keeffe E, Atillasoy E, Varshneya R, Bergstein G. *Gastroenterology* 2005;128:A739.
230. Cost-effectiveness of entecavir vs. lamivudine with adefovir salvage as first-line treatment in HBeAg-positive chronic hepatitis B: Analyses based on two-year results from a randomized clinical trial. Veenstra DL, Iloeje UH, Sullivan SD, Tafesse E, Cross A, **Di Bisceglie A**, Kowdley K, Gish RG. *Am J Gastroenterol* 2005 (in press).

231. A phase I safety and immunogenicity trial of a novel E1E2/MF59c1 hepatitis C vaccine candidate in healthy HCV-negative adults. Frey SE, **Di Bisceglie AM**, Gorse GJ, Ray R, Houghton M, Schultze V, Abrignani S, Coates S, Belshe R. *Hepatology* 2005;42:750A.
232. Iron and *HFE* gene mutations in advanced chronic hepatitis C (CHC): Results from the lead-in phase of the HALT-C Trial. Bonkovsky HL, **Di Bisceglie AM**, et al. *Hepatology* 2005;42:548A.
233. Interim safety analysis of patients enrolled in the randomized, international retreatment with Pegasys in patients not responding to prior peginterferon alfa-2B/ribavirin (RBV) combination therapy (REPEAT) study. Marcellin P, Freilich B, Andreone P, Brandao-Mello CE, **Di Bisceglie AM**, et al. *Hepatology* 2005;42:6570A.
234. Peginterferon alfa-2a (40KD) plus ribavirin (RBV) in pegylated interferon alfa-2b (12kD)/ribavirin nonresponders: Week 12 efficacy and safety outcomes of the REPEAT Study. Jensen D, **Di Bisceglie AM**, Gitlin N, Freilich B, Reddy KR, Feinman V, Arora S, Marcellin P. *Gastroenterology* 2006;130:A836.
235. Peginterferon alfa-2b (40KD) (PEGASYS) plus ribavirin (RBV) (Copegus) in pegylated interferon alfa-2b (12kD)/ribavirin nonresponders with cirrhosis/advanced fibrosis: Interim analysis of the REPEAT Study. Gitlin N, **Di Bisceglie AM**, Marcellin P, Bonkovsky H, Rai R, Rizzetto M, Teuber G, Jensen D. *Gastroenterology* 2006;130:A838.
236. Cost effectiveness of antivirals in HBeAg-positive chronic hepatitis B: Impact of seroconversion and viral suppression. Veenstra DL, Iloeje UH, Tafesse E, Sullivan SD, Cross A, **Di Bisceglie AM**, Gish RG. *Gastroenterology* 2006;130:A847.
237. Estimating the burden of liver disease in the United States using administrative claims data. **Di Bisceglie AM**, Gavard JA, Stirneman P, Xiao H, Burroughs TE, Schnitzler MA, Takemoto SK. *Gastroenterology* 2006;130:A812.
238. Smoking increases the risk of hepatocellular carcinoma in cirrhosis. Abdelaziz A, Dakjil N, Elbaz T, Shebab H, Zekri A, **Di Bisceglie AM**. *Liver International* 2006;26:63.
239. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Lai C-L, Gane E, Hsu C-W, Thongsawat S, Wang Y, Chen Y, Heathcore EJ, Rasenack J, Bzowej J, Nauomov N, Zeuzem S, **Di Bisceglie AM** et al. *Hepatology* 2006;44:222A.
240. Mutations in genotype 1A HCV of liver cancer patients occur in the +1 reading frame, not in the core protein. Fishman S, Balestrieri C, Fan X, Xing J, **Di Bisceglie AM**, Branch AD. *Hepatology* 2006;44:309A.
241. Clinical, biochemical, virologic and histologic outcomes of chronic hepatitis C following sustained virologic response (SVR) to HCV therapy: A prospective 5 year cohort study. **Di**

- Bisceglie AM**, George SL, Mihindulasuriya L, Hoffman J, Bacon BR. *Hepatology* 2006;44:315A.
242. Quality of care in chronic hepatitis C virus (HCV) infection. Kanwal F, Spiegel BM, Goetz M, Gralnek IM, Dominitz JA, **Di Bisceglie AM**, Asch S. *Hepatology* 2006;44:673A
243. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. **Di Bisceglie AM**, Lai C-L, Gane E et al. *Hepatology* 2006;44:230A.
244. Serum fibrosis markers predict future clinical decompensation in primary biliary cirrhosis better than liver biopsy, bilirubin or Mayo risk score. Mayo MJ, Parks J, Huet B, Combes B, Mills SA, Markin R, Rubin R, Wheeler D, Contos M, West B, Saldana S, Getachew Y, Butsch R, Luketic VA, Peters M, **Di Bisceglie AM**, et al. *Hepatology* 2006;44:630A.
245. The prevalence of viral hepatitis with cirrhosis and hepatocellular carcinoma (HCC) in Egypt. Ryu SH, Kumari R, Osmack P, Xu Y, Fan X, Omar A, **Di Bisceglie AM**. *Gut and Liver* 2007;1;(suppl 1):72.
246. Therapy of hepatitis C. **Di Bisceglie AM**. *Gut and Liver* 2007;1;(suppl 1):46.
247. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine treated patients with chronic hepatitis B (the GLOBE study). Zeuzem S, Gane EJ, Liaw YF, **Di Bisceglie AM** et al. *Hepatology* 2007;46:A994.
248. On-treatment virologic suppression at week 24 decreases the risk of histologic progression at 1 year: Data from the GLOBE trial. Benhamou Y, **Di Bisceglie AM**, Goodman ZD et al. *Hepatology* 2007;46:A995.
249. Retreatment of treatment experienced HCV patients with pegylated interferon alfa-2A and thymosin alpha-1: Pooled analysis of two randomized controlled trials. Sherman KE, Gordon SC, Iftikhar R, Rodriguez-Torres M, Rustgi VK, **Di Bisceglie AM** et al. *Hepatology* 2007;46:A1331.
250. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial **Di Bisceglie AM**, Shiffmann ML, Everson GT et al. *Hepatology* 2007;46:LB1.
251. Pegylated interferon alfa-2A (40kD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2B (12kD)/RBV: Final efficacy and safety outcomes of the REPEAT study. Jensen DM, Freilich B, Andreone P, **Di Bisceglie M** et al. *Hepatology* 2007;46:LB4.

252. Hepatocellular carcinoma: Why early diagnosis is needed. **Di Bisceglie AM**. *Global Antiviral Journal*. 2007;3(suppl 2):41.
253. Marcellin P, Freilich BL, Andreone P, **Di Bisceglie AM** et al. Type of response to prior pegylated interferon alfa-2b (12kD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2a (40kD)/RBV. *Gastroenterology* 2008;134:A-787.
254. Marcellin P, Freilich BL, Andreone P, **Di Bisceglie AM** et al. HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2b/RBV: Results from REPEATstudy. *Gastroenterology* 2008;134:A-788.
255. Jensen DM, Freilich BL, Andreone P, **Di Bisceglie AM** et al. Easy-to-assess on treatment parameters correlate with degree of virological response after 12 weeks of treatment. *Gastroenterology* 2008;134:A-788.
256. Jensen D, Freilich B, Andreone P, **Di Bisceglie AM** et al. Easy to assess on-treatment parameters correlate with degree of virological response after 12 weeks of treatment. *J Hepatol* 2008;(suppl. 2);48:S297-S298.
257. Marcellin P, Freilich B, Andreone P, **Di Bisceglie AM** et al. HCV-RNA status at week 12 of treatment with peginterferon alfa-2A/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2A/RBV: results from the REPEAT study. *J Hepatol* 2008;(suppl. 2);48:S301.
258. Marcellin P, Freilich B, Andreone P, **Di Bisceglie AM** et al. Type of response to prior pegylated interferon alfa-2B (12KD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2A(40KD)/RBV. *J Hepatol* 2008;(suppl. 2);48:S301.
259. **Di Bisceglie AM**, Hassanein TI, Jeffers LJ et al. Association of pretreatment and on-treatment factors with null response in patients with chronic hepatitis C treated with peginterferon alfa-2° and ribavirin. *J Hepatol* 2008;(suppl. 2);48:S292.
260. Lok AS, Seeff LB, Morgan TR, **Di Bisceglie AM** et al. Incidence and risk factors associated with hepatocellular carcinoma (HCC) in patients with advanced liver disease due to hepatitis C: results of the HALT-C Trial. *J Hepatol* 2008;(suppl. 2);48:S45.
261. Sterling R, **Di Bisceglie AM**, Curto T, Morgan TR, Seeff LB, Hoefs JC, Goodman ZD, Lok AS. Occurrence of hepatitis C-related hepatocellular carcinoma in the absence of cirrhosis: results from the HALT-C Trial. Second Annual Conference of the International Liver Cancer Association. Chicago, September 5-7, 2008.
262. Fishman S, Factor S, Balestrieri C, Desai SM, **Di Bisceglie AM**, Benson D, Branch AD. HCV in liver cancer patients has characteristic mutations in the core gene. *Hepatology* 2008;48:342A.

263. Mehta A, Marrero J, Junaidi O, **Di Bisceglie AM**, Block TM. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. *Hepatology* 2008;48:362A.
264. McHutchison JG, Shiffman ML, Terrault N, Manns MP, **Di Bisceglie AM** et al. A phase 2B study of telaprevir with peginterferon-alfa-2A and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa-2A/B and ribavirin therapy: PROVE3 interim results. *Hepatology* 2008;48:431A.
265. Morishima C, **Di Bisceglie AM**, Koziel MJ et al. Antigen-specific lymphocyte proliferation decreases over time in advanced chronic hepatitis C and its loss is associated with the presence of cirrhosis. *Hepatology* 2008;48:785A.
266. Marcellin P, Craxi A, Brandao-Mello CE, **Di Bisceglie AM** et al. A 72 week treatment duration with peginterferon alfa-2A (40kD) (PEGASYS) plus ribavirin (Copegus) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2B (12kD) plus ribavirin: Findings of the multinational REPEAT study. *Hepatology* 2008;48:1147A.
267. McHutchison JG, Manns MP, Muir A, Terrault N, Jacobson IM, Afdhal NH, Heathcote J, Zeuzem S, Reesink HW, Bsharaf M, George S, Adda N, **Di Bisceglie AM**. PROVE# Final Results and 1-year durability of SVR with Telaprevir-Based regimen in hepatitis C genotype-1 infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2A/B and ribavirin therapy. *Hepatology* 2009;50:334A-335A.
268. Singal A, Volk ML, Jensen DM, **Di Bisceglie AM**, Schoenfeld P. The natural history of hepatitis C treatment failures: A meta-analysis. *Hepatology* 2009;50:647A.
269. Kanwal F, Befeler A, Xu C, Zerinque A, **Di Bisceglie AM**. Rate of curative treatment for early stage hepatocellular carcinoma – Results from the Liver Cancer Research Network. *Hepatology* 2009;50:1087A.
270. **Di Bisceglie AM**, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow K, Stoddard A. Patient Mortality and Liver Transplantation during the HALT-C Trial: Relationship to Chronic Liver Disease and Interferon Therapy. Presented at DDW 2010, New Orleans, LA.
271. Dienstag JL, Bonkovsky HL, Kim H-Y, Seeff LB, **Di Bisceglie AM**, Szabo G, Wright EC. Progression of Advanced Chronic Hepatitis C (CHC): Further Follow-up Results from the HALT-C Trial. Presented at DDW 2010, New Orleans, LA.
272. Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2A/ribavirin in patients with chronic hepatitis C. Chung RT, **Di Bisceglie AM**, Poordad FF et al. *J Hepatol* 2010;52:S106.

273. Improved sustained virologic response (SVR) rates in “difficult-to-cure” patients treated with telaprevir in combination with peginterferon alfa-2A and ribavirin: An analysis from the PROVE3 study. Manns MP, Muir AJ, Adda N, McHutchison JG, Terrault N, Bengtsson L, George S, **Di Bisceglie AM**. *J Hepatol* 2010;52:S115.
274. Early virological response profiles with telaprevir (T) in combination with peginterferon-alfa-2A (P) and ribavirin in genotype 1 HCV treatment-naïve and treatment-experienced patients are similar. Poordad F, McHutchison JG, Shiffman ML, Berg T, Muir AJ, Manns MP, **Di Bisceglie AM** et al. *J Hepatol* 2010;52:S121.
275. Pharmacogenomic analysis reveals improved virologic response in all IL-28B genotypes in naïve genotype 1 chronic HCV patients treated with GI-5005 therapeutic vaccine plus PEG-IFN/Ribavirin. McHutchison JG, Thompson AJ, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Vierling JM, Shiffman ML, Brown RS, **Di Bisceglie AM** et al. *J Hepatol* 2010;52:S457.
276. Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients (pts) with advanced chronic hepatitis C (CHC): extended follow-up results from the HALT-C Trial. Anna S. Lok, James E. Everhart, Elizabeth C. Wright, Timothy R. Morgan, **Adrian M. Di Bisceglie**, Hae-Young Kim, HALT-C Trial Group. *Hepatology* 2010;52;429A
277. Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers (AFP, AFP-L3, and DCP) in Patients (pts) with Chronic Hepatitis C (CHC) and Advanced Fibrosis with and without HCC. Richard K. Sterling, Elizabeth C. Wright, Timothy R. Morgan, Leonard B. Seeff, John C. Hoefs, **Adrian M Di Bisceglie**, Jules L. Dienstag, Anna S. Lok, HALT-C Trial Group. *Hepatology* 2010;52;328A.
278. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naïve patients: Final results of phase 3 ADVANCE study. Jacobson IM, McHutchison JG, Dusheiko GM, **Di Bisceglie AM** et al. *Hepatology* 2010;52;427A.
279. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102): preliminary analysis. Marcellin P, Buti M, Krastev Z, Gurel S, **Di Bisceglie AM** et al. *Hepatology* 2010;52;555A.
280. Telaprevir in combination with peginterferon alfa-2A and ribavirin: Analyses of pre-defined subpopulations in the phase 3 ADVANCE trial. Marcellin P, Jacobson I, Zeuzem S, Bzowej N, Muir AJ, Dusheiko G, Reddy R, Adda N, Bengtsson L, Kauffman RS, George S, **Di Bisceglie AM**. *J Hepatology* 2011;54:S183.
281. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the ADVANCE and Illuminate phase 3 studies. Sulkowski MS, Reddy R, Afdhal NH, **Di Bisceglie AM** et al. *J Hepatology* 2011;54:S195.

282. Vx-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: Zenith study interim results. **Di Bisceglie AM** et al. *J Hepatology* 2011;54:S540.
283. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies. Poordad F, Sulkowski M, Reddy R, **Di Bisceglie AM**, Zeuzem S, Afdhal N, Bengtsson L, Wright CI, Kauffman RS, Adda N. Presented at DDW 2011, abstract #626 and *Can J Gastro* 2012;26(suppl):178A.
284. Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial. **Di Bisceglie AM**, Dusheiko GM, Muir AJ, Zeuzem S, Marcellin P, Bzowej NH, Jacobson IM, Adda N, Bengtsson L, Kauffman RS, George S, Reddy R. Presented at DDW 2011, abstract #832.
285. Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage. Marcellin P, Sullivan J, Fried MW, Kieffer TL, Dusheiko GM, Martin EC, Nelson DR, **Di Bisceglie AM** et al. *Hepatology* 2011;54:1348A and *Can J Gastro* 2012;26(suppl):81A.
286. Vx-222/telaprevir in combination with peginterferon-alfa-2A and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR12 interim results. Nelson DR, Gane EJ, Jaconson IM, **Di Bisceglie AM** et al. *Hepatology* 2011;54:1435A and *Can J Gastro* 2012;26(suppl):79A.